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Dystrophinopathies can be distinguished in two classic phenotypes, Duchenne muscular 
dystrophy (DMD) and Becker muscular dystrophy (BMD).1 Both disorders are well known 
for the muscle symptoms and weakness, which first affects the lower limbs and subse-
quently the upper limbs. Historically, the clinical difference between BMD and DMD was 
defined by the progression of the muscle weakness. Early natural history studies have re-
ported that in general boys with DMD would become wheelchair-bound before the age 
of 13 whereas in boys with BMD ambulation should be preserved at the age of 16 years.1 
Since the pathogenesis of dystrophinopathy has been discovered, immunological and 
molecular-genetic studies have provided better insight in the difference between both 
phenotypes. Although the two disorders have many similarities the heterogeneity of both 
disorders is intriguing. For example, the severity of muscle weakness and the age of onset 
in BMD is much more heterogeneous than in DMD and may result in different presenta-
tions and a larger differential diagnosis in the diagnostic work up. Other heterogeneous 
clinical aspects of dystrophinopathies are cognitive and behavior problems and cardiac 
involvement; rarely these are presenting symptoms.2-6
Diagnosis in historical perspective
DMD was described in the 19th century by the French neurologist Guillaume Duchenne 
de Boulogne and the English physician Edward Meryon separately.1 The latter reported 
a familial trait of the disease with predilection in males and he described from autop-
sies that a pathological substrate for the paralysis could be found in destroyed muscle 
fibres with specific involvement of the sarcolemma.1 Duchenne was able to obtain muscle 
specimens in life by means of a needle-harpoon and he observed different stages of the 
disease pathologically.1, 7 BMD was first described by Kostakow in 1937, and recognized as 
a novel X-linked muscular dystrophy distinct from Duchenne muscular dystrophy by the 
German neurologist and geneticist Peter E. Becker and the psychologist Franz Kiener in 
1955.1, 8 They provided detailed clinical descriptions of affected males with a X-linked in-
heritance pattern among multiple generations within large families; the age of onset was 
between 12 -25 years with proximal weakness in the lower limbs which was slowly pro-
gressive and extended to the arms usually 5-10 years after the first symptoms had started 
in the legs.8 Since the identification of dystrophin in 1987 disturbed dystrophin synthesis 
could be assessed by means of immunological investigation of muscle tissue, which en-
abled distinguishing a dystrophinopathy from other limb girdle muscular dystrophies. In 
DMD dystrophin is virtually absent and in BMD dystrophin is present but in a decreased 
amount and/or in altered size.9 Genetically, DMD and BMD are X-linked and allelic, and are 
caused by a mutation in the DMD gene.10 In most cases mutations that lead to a disturbed 
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reading frame cause lack of dystrophin production which results in a DMD phenotype.11 
In general, mutations that leave the reading frame intact result in synthesis of a shortened 
or longer, but still functional, dystrophin and a BMD phenotype. At present, diagnosis of 
dystrophinopathies still starts with a good description and interpretation of the clinical data .
Clinical characteristics
Muscle symptoms in Duchenne muscular dystrophy
Among the muscular dystrophies DMD is the most frequent variant with an incidence 
of 10.71 to 27.78 per 100,000 live born males and a prevalence of 4.78 (95% confidence 
interval 1.94-11.81) per 100,000 males.12 The onset is typically in childhood and should be 
present before the age of five years according to the European Neuromuscular center 
(ENMC) diagnostic criteria .13 The mean age at which first symptoms of DMD were noticed 
is 2,5 years (SD 1.4, range 0,2-6.1 years).14 The boys often have an unsteady waddling gait 
with tiptoe walking. They may also be delayed in starting to walk; one third of the boys 
started to walk after 19 months, but in general all DMD patients will be able to walk before 
the age of three years.1 Enlarged calves, caused by hypertrophy of the calf muscles may be 
an early sign for the clinician. However, the reported mean age at diagnosis was around 4.9 
years 14, 15 which suggests that early symptoms are not always recognised. A positive family 
history may be helpful for early diagnosis but in approximately 30% of the patients the 
mutation is de novo and then the family history is negative. The muscle weakness in DMD 
is symmetrical and progressive with the proximal muscles more affected than the muscles 
in the distal limbs.13 An important early sign of weakness in the proximal leg muscles is the 
Gowers’ sign, in which the child uses his arms climbing up his legs when he raises from 
sitting on the floor to standing position. Fasciculations and sensory disturbances suggest 
a neurogenic disorder and are exclusion criteria.13 Although muscle strength usually im-
proves in toddlers with DMD they will not be able to run. Following a plateau phase, which 
is usually reached at age 4-8 years,16 muscle weakness progresses, not only in the upper 
legs but also in muscles of the lower legs, proximal arm and neck muscles. During the pro-
gressive phase ambulation will be lost, in historical series in or before adolescence. Since 
the introduction of steroid treatment in the 1990’s, loss of ambulation can be delayed for 
at last a year. In puberty, there is a risk to develop scoliosis due to weakness of the spinal 
muscles in combination with fast length growth. At a later stage of the disease respiratory 
muscles become weak resulting in reduced pulmonary function. Often the first sign is 
nocturnal hypoventilation and hypercapnia.
c-straathof-binnenwerk_zw_100gprint_3mmbleed-versie2.indd   12 15-9-2014   13:25:38
Diagnostic considerations in dystrophinopathies
13
1
Muscle symptoms in Becker muscular dystrophy 
Clinically, muscle symptoms in BMD are more heterogeneous than in DMD, ranging from 
very mild, such as exercise induced myalgia or cramps, to severe, like progressive weak-
ness in the upper legs.13 Often calf hypertrophy is present, but this is not a specific sign17 
and may be lacking.18 Weakness of the quadriceps femoris muscles can be the only sign for 
a long time. Usually at a later stage the upper limbs become affected as well. In sporadic 
cases with proximal weakness the differential diagnosis should include limb girdle mus-
cular dystrophy (LGMD)19, 20 or spinal muscular atrophy (SMA).21 Presence of fasciculations 
or sensory disturbances excludes BMD.13 As in DMD a positive family history of X-linked 
inheritance may be helpful for the diagnosis. However in a patient with a de novo muta-
tion the symptoms will interpreted as a sporadic case. The estimated birth incidence of 
BMD is about one-third to one-fifth of the incidence of DMD.22, 23 A recent meta-analysis 
estimated that the prevalence among males worldwide is 1.53 (95% confidence interval 
0.26-8.94) per 100.000.12 BMD seems to be difficult to recognize in some patients as it was 
reported that though 90% had symptoms at age 20, diagnosis was often made at an older 
age; only 50% was diagnosed at the age of 15 years and 90% diagnosed at age 35.24 Rarely, 
progressive weakness presented in the third until even the sixth decade.25-28
Intermediate dystrophinopathy 
Sometimes the phenotype is milder than expected for DMD because weakness is less 
progressive and/or ambulation is preserved longer but not as good as one expects in 
BMD. Michael Brooke introduced in 1983 the term “outliers” in a natural history study of 
114 DMD patients. Ten patients of 8 years and older were performing better on climbing 
stairs than the rest.29 It was suggested that dystrophinopathies could represent a spec-
trum with several phenotypes or that these outliers might be genetically different. Indeed 
when levels of dystrophin in muscle biopsies were related to the clinical phenotype, three 
groups could be distinguished: DMD patients who had little or no dystrophin (< 3%), BMD 
patients who were having more qualitative than quantitative abnormalities in dystrophin 
and a third group with intermediate dystrophy (outliers); these patients had reduced 
amounts of dystrophin (3-60 % of normal).9 In addition, patients with milder phenotypes 
have been described in relation to specific mutations such as deletions of exon 3-7 of the 
DMD gene.30 In clinical studies the terms outlier and intermediate dystrophinopathy appar-
ently have not got much support as very few publications on this topic can be found.
Female carriers of dystrophinopathy
In two-third of the patients with dystrophinopathy the mutation has been transmitted by 
the mother, who is carrier, and in one-third the dystrophinopathy is due to a new (de novo) 
mutation in the affected male. In the latter the mother is not a carrier somatically, although 
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she may have germ line mosaicism.31 If the mother is carrier of a mutation in the DMD 
gene her daughters have a 50% risk to carry the same mutation and if so to transmit the 
mutation to their offspring. Also her sisters and maternal female family members may be 
carriers. In a recent study one-third of the adult potential carriers had not been tested for 
carrier status.32 Female carriers are often asymptomatic but can have muscle symptoms 
like myalgia, hyperCKemia, and muscle weakness. In a large Dutch cohort of 129 female 
carriers 22% was symptomatic (26% of the DMD carriers; 13% of the BMD carriers) of whom 
17% had mild to moderate muscle weakness.33 
Cardiac involvement in dystrophinopathy 
Cardiac muscles may be involved in all dystrophinopathies and, if so, this can result in 
cardiac arrhythmias and/or dilated cardiomyopathy. In DMD cardiac involvement is usually 
diagnosed around the age that ambulation is lost.34 Often it is asymptomatic but pro-
gressive. Currently screening with yearly ECG/echocardiography is advised at young age 
aiming at pharmacological intervention when first abnormalities are detected in order to 
prevent heart failure.34, 35
In BMD heart failure can be the presenting symptom,5, 36 and cardiomyopathy occurs in 
the majority of the BMD patients during the course of the disease.36 Dystrophin amounts 
of 30 % quantified by Western Blotting analysis seem to be sufficient to avoid weakness in 
skeletal muscles, as is found in families with in-frame mutation in the DMD gene, but did 
not protect against severe cardiac pathology.37
Concerning female carriers, the majority had cardiac abnormalities on ECG and/or echo-
cardiography. 38, 39 Left ventricular dilatation occurred in 18% of dystrophinopathy carriers 
(19% of DMD, 16% of BMD carriers).39 During follow up dilated cardiomyopathy was found 
in 10%.38 Regular cardiac screening is advised for all adult DMD/BMD carriers 40 but only 
two-third of the carriers was aware of their cardiomyopathy risk when questioned.41
Cognition and behavior problems in dystrophinopathy
Besides muscle involvement in DMD it is known that the prevalence of cognitive deficit is 
higher in DMD. The mean full-scale IQ is one SD below the IQ in the normal population. 
Approximately 30% of the boys with DMD have mental retardation with an IQ < 70.42 In con-
trast to the progressive nature of muscular weakness in DMD the cognitive deficit seems to 
be stable. In addition learning problems especially with reading and spelling occur more 
frequently in DMD.43 The reading age and reading performance was significantly lower in 
DMD boys of 8.5-13.5 years old compared to aged matched patients with SMA and healthy 
controls.44 DMD is also associated with several behavioral disorders. Firstly, the reported 
c-straathof-binnenwerk_zw_100gprint_3mmbleed-versie2.indd   14 15-9-2014   13:25:38
Diagnostic considerations in dystrophinopathies
15
1
prevalence of attention-deficit hyperactivity disorder (ADHD) is 12-33%.45, 46 which is two to 
five fold the prevalence in a general school population.47 Secondly, about 3% was reported 
to be diagnosed with an autism spectrum disorder which is also increased compared to 
0.16% in the general population.45, 48 Finally, in almost 5% an obsessive-compulsive disorder 
(OCD) was reported, twice as high as compared to the general population.45
In patients with BMD limited studies on cognition have been performed. Mental retarda-
tion has been reported as a presenting symptom in combination with elevated CK levels.6 
The four patients described were aged 15-42 years and all had a IQ below 70; besides calf 
enlargement in one and occasional muscle cramps and a mild scoliosis in another, none 
of them had muscle weakness on neurological examination. CK levels were elevated, with 
levels of 2550, 7500, 896 and 730 U/l (normal < 240 U/l) in respectively the patients aged 15, 
17, 19 and 42 years old. In addition, a mean full scale IQ (FSIQ) of 83 (± 25) has been reported 
in a series of 115 patients with BMD.49 The low IQ was confirmed recently in a small series of 
13 BMD patients (11 adults) with a mean FSIQ of 86 (± 10.4).50 In contrast, in a series of 24 Aus-
tralian BMD patients (median age 14.2 y; range 6-43.2) in whom IQ and neuropsychological 
profile was investigated, the mean FSIQ was reported to be normally distributed with a 
mean of 95.6 (± 23.3);51 in twelve of them (52%) the scores on the FSIQ ranged between 
85-115. However in three others (13%) the FSIQ was below 70 and in two others ≥ 130. The 
FSIQ was not related to severity of clinical symptoms but a correlation with socioeconomic 
status was found; a lower IQ was found in patients with a lower socioeconomic status. 
Moreover, in this study, 21% of the patients had reading problems and 32% had spelling 
difficulties. Two patients were autistic. Eleven parents completed a checklist on behavior 
disorders and they reported behavior compatible with ADHD in four children. In general, 
clinically relevant behavior problems were reported in eight children. This seems a high 
number, compared to reported frequency of 14.1% in the general (Australian) population.51, 52 
Resuming, cognition as well as reading performance and behavior appear to be heteroge-




The enzyme creatine kinase (CK) plays an important role in cellular energy genera-
tion in the muscles, because it enables the (reversible) phosphorylation of creatine to 
creatine-phosphate. Creatine-phosphate serves as an energy reserve in muscles as it can 
donate a phosphate group to adenosine diphosphate (ADP) to form adenosine triphosphate 
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(ATP) and creatine during intense muscular activity. The serum CK level is the standard 
laboratory test for creatine kinase and is often used as a marker of functional status of 
muscle tissue. The total serum CK level reflects three iso-enzymes: CK-MM (predominant-
ly present in skeletal muscles), CK-MB (present in cardiac muscle), and CK-BB (present in 
brain).53 High CK-MB levels are related to myocardial damage such as acute myocardial in-
farction or cardiomyopathy. Elevated CK-BB can be found following epileptic seizures or 
following stroke. Elevated CK-MM is associated with neuromuscular diseases and in this 
chapter the focus will be on CK-MM which, if elevated in serum, will result in an increased 
total serum CK level. Increased CK levels can be a parameter for muscle disorders, like mus-
cular dystrophies, hereditary, inflammatory and toxic myopathies. In addition, CK is often 
mildly elevated, to 5 times the upper limit of normal, in neurogenic disorders like hereditary 
spinal muscular atrophy (SMA), motor neuron disease (MND) and axonal neuropathy. In 
daily practice an increased level can be important whereas a low CK is not clinically rele-
vant. Therefore only the upper limit of normal range is used to discriminate pathological 
from physiological levels. The measured value can vary intraindividually on different test 
moments. Each diagnostic laboratory has its own population based reference values of the 
normal range. For example, in the Leiden University Medical Center the upper limit is 170 
U/l in males and 140 U/l in females. Gender and racial differences have been described as 
the upper limit of normal range is higher in males and almost doubled in black people.54
Rule of the thumb is that CK is always increased in dystrophinopathy. Elevated CK level can 
be the sign which is noticed first in dystrophinopathy. In DMD CK levels can exceed the 
upper limit of normal more than 100 times especially at young age. In progressive disease 
fat replaces muscle tissue and thus functional muscle tissue is lost; the serum CK levels can 
be lower then, but will still be elevated. In BMD the CK level is also increased, but lower 
levels have been described than in DMD.55 In adult males with more muscle weakness the 
tendency is that CK levels decrease. Besides, in families with mild BMD youngsters had an 
increased CK and adults had normal levels.56 In asymptomatic female DMD carriers the CK 
level can also be mildly increased.33 Elevated CK level can serve as an important clue in 
diagnosis of dystrophinopathy, but is not specific for this disorder; moreover hyperCKemia 
is frequently observed in patients with a wide range of muscle disorders. Therefore hyper-
CKemia will be discussed from different perspectives in the next paragraphs.
HyperCKemia not related to neuromuscular disorders
The prevalence of incidentally elevated CK in a large Norwegian cohort of 12828 subjects 
(age range 30-87y) who participated in a population based health survey (Tromsø study), 
was reported 5.3% which decreased to 1.3 % following a second measurement with a stan-
dardised control test three days after refraining from exercise and alcohol. Because statin 
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use or known disorders could explain the hyperCKemia in 46% of the cases with persistent 
hyperCKemia, the prevalence of idiopathic hyperCKemia in the general population was es-
timated at 0.71%.57 A frequently reported cause of acquired hyperCKemia is statin treatment 
for hyperlipidaemia, in cardiovascular or cerebrovascular disease, which can result in asymp-
tomatic elevated serum CK levels or symptomatic hyperCKemia with muscular symptoms 
such as myalgia, myopathy but also life threatening rhabdomyolysis. The mechanism is not 
clearly elucidated and a genetic susceptibility is suggested.58 In patients who are evaluated 
clinically after discontinuation of the statin rarely a neuromuscular disorder was diagnosed; 
for example myotonic dystrophy, McArdle’s disease, mitochondrial myopathy and Kenne-
dy ś disease, which apparently had been subclinical before the start of statin treatment.59, 
60 Elevated CK has also been reported in patients treated with other medication including 
beta-blockers, retinoic acid, antiretroviral treatment and clozapine as well as following sub-
stance abuse like alcohol, cocaine and heroin.53 Traumatic muscle injury, strenuous exercise, 
heavy manual labour or intramuscular injections are other acquired causes of hyperCKe-
mia in otherwise healthy people.61 In healthy people a 50-fold increase has been found in 
post-exercise CK levels;62 this was more pronounced in males than in females and occurred 
more frequently in black people and in untrained people. Military recruits in whom exer-
tional rhabdomyolysis was observed following basic military training were often asymp-
tomatic.63 A single muscle cramp can result in a threefold increased CK within 6 hours and 
nearly fivefold at 30 hours.64 Exercise or cramp related hyperCKemia will decrease sponta-
neously after a resting period of several days. However, persistent hyperCKemia is described 
in asymptomatic healthy subjects65 and in athletes.66 A possible underestimated phenom-
enon is the macro-CK which represents CK variants with a molecular mass > 200 kDa. This 
is much higher than the molecular mass of 80 kDa of the “common ” CK iso-enzymes.67 
The prevalence of macro-CK in hyperCKemia is around 4%.68 Two types of macro-CK are 
known: type 1 is a benign complex of CK iso-enzymes with either immunoglobulin IgG or 
IgA which will increase the serum half-life due to the high molecular weight. Its reported 
prevalence in the general population is 0.43-1.2% and it is associated with autoimmune 
myositis.53 Type 2 has a prevalence of 0.5-3.7% in the general population but is prognostic 
unfavourable because it is associated with liver tissue necrosis or malignancies. This type of 
macro-CK encompasses oligomeric mitochondrial CK. Macro-CK can be determined with 
electrophoresis69 but not all laboratories perform this diagnostic analysis. 
Idiopathic hyperCKemia
The term idiopathic hyperCKemia was introduced in 1980 to describe patients with per-
sistent elevated CK levels despite normal neurological examination and diagnostic work up 
including EMG and muscle biopsy.53, 70 In addition, familial idiopathic hyperCKemia has been 
reported.71 Forty-one subjects of 13 families had elevated CK 1.2-7.7 times. The family trait of 
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hyperCKemia in most pedigrees was autosomal dominant with a higher penetrance in men 
and male-to-male transmission in eight families. Muscle biopsies showed no abnormalities 
or non-specific features such as increased variance in fibre size. The prognosis was favour-
able in all families without progression to weakness. Also long term prognosis in sporadic 
idiopathic hyperCKemia seems to be favourable.57, 72-74 In 31 patients (87% males) with idio-
pathic hyperCKemia, who all had had muscle biopsy at referral, follow up was possible with 
a mean interval of 7.2 years (range 4-18 years) in 23 cases and none showed clinical deterio-
ration besides one patient who had developed axonal polyneuropathy.74 In another series 
of 55 predominantly male cases out of originally 93 cases with undiagnosed hyperCKemia, 
with a mean interval between referral and clinical follow up of 7.5 years (range 4-15 years) 
the yield was one subject with limb girdle weakness, three cases with thyroid abnormalities, 
one dystrophinopathy carrier and one possible SMA carrier.73 Interestingly, 78% had per-
sistent hyperCKemia but in all but one subject the CK level at follow up had decreased com-
pared to the initial CK level. In one female the CK had increased from the range of 194-554 
U/l at referral to a value in the range of 555-1038 U/l at follow up; subsequently, neurological 
examination revealed that she had weakness with a limb girdle pattern. In a case-control 
follow up study of the aforementioned population based Tromsø study 120 subjects (66 
women, 54 men) with persistent hyperCKemia participated as case.75 Muscle symptoms like 
cramps and muscle pain or stiffness were reported in 71% of these cases compared to 54% 
in controls (p=0.017). In only five cases hyperCKemia could be related to a muscle disorder 
although muscle biopsies were not part of the study protocol. Three cases were newly di-
agnosed as unclassified myopathies, one female was known with the diagnosis facioscapu-
lohumeral dystrophy (FSHD) and one male suffered from polymyositis. This indicates that 
hyperCKemia in a general population is rarely associated with a neuromuscular disorder. 
HyperCKemia and the risk of dystrophinopathy
Is dystrophinopathy excluded in asymptomatic hyperCKemia?
Retrospective evaluation of 114 asymptomatic predominantly male patients aged be-
tween 3-70y (mean age 33) with increased CK (mean 1410 units/l, range 246-9082) resulted 
in diagnosis of a neuromuscular disorder in 21 patients (18,4%) by means of muscle biopsy 
and/or EMG.76 Five cases (one adult with myalgia and four asymptomatic children) were 
diagnosed with dystrophinopathy, two of them had normal histology and immunohis-
tochemical dystrophin expression in muscle samples. Immunoblotting however was not 
performed and the dystrophinopathy was confirmed by DNA analysis. 
Often CK and biopsy findings are combined when diagnostic yield was reviewed. Dabby 
et al.77 evaluated muscle biopsies of 40 cases with hyperCKemia with mild or no symptoms 
(male to female ratio 3:1, age 7-67 years), and observed non-specific histopathological ab-
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normalities in 22 patients. Subsequently, immunohistochemical staining for dystrophin 
antibodies could classify three asymptomatic patients in whom abnormal dystrophin was 
found, which was compatible with BMD. Fernandez et al.78 also reviewed muscle biopsy 
specimens of 104 patients with persistent CK levels > 500 units/l and no or mild symp-
toms. The mean age was 40 years (range 4-79y) and 71% of the cases was male. In 57 
cases a diagnosis could be established: seven males with dystrophinopathy (not specified) 
and one carrier of dystrophinopathy. Dystrophinopathy represented 14% of the confirmed 
diagnoses and was established in 7.7% of the cohort. The probability of a diagnosis was 
increased if CK levels were > 10 times elevated and in cases younger than 15 years.78 Nota-
bly, dystrophinopathy can present with mild symptoms like post-exertional myalgia and 
cramps,79, 80 cardiac failure,5, 81 or non-muscular symptoms like behavior problems,82 speech 
delay4 or cognitive problems.3, 6 Often the combination with hyperCKemia may raise the 
suspicion of an underlying muscular dystrophy and further analysis will be performed. 
However normal serum CK levels as well as normal histology in muscle biopsies have been 
described in BMD cases. Also female carriers of DMD often have a mildly elevated CK.
In conclusion, CK is an important signal in early diagnosis, and asymptomatic hyperCKe-
mia will not rule out BMD neither will a normal CK in adult patients with mild muscles 
symptoms.56 The question is which patients with mild symptoms will benefit from exten-
sive diagnostic work up.
Differential diagnosis and diagnostic algorithms in hyperCKemia
Several diagnostic algorithms for asymptomatic /pauci-symptomatic hyperCKemia were 
proposed by different groups. The Italian Association of Myology approved an algorithm 
in 2006.83 One of the co-authors also contributed to the European Federation of Neu-
rological of Societies (EFNS) guidelines published in 2010.84 More recently an American 
paper reviewed the state of the art in hyperCKemia and proposed a diagnostic flow-
chart.53 The algorithms have much in common, such as the first step in all is exclusion of 
non-neuromuscular causes of hyperCKemia including macroCK. In the EFNS guidelines 
a redefinition is proposed to define hyperCKemia as values above 1.5 times the upper 
limit of normal CK and correct for gender and race. It will increase the specificity of the 
test to screen for neuromuscular disorders with an acceptable reduction in sensitivity.85 
The American diagnostic flow-chart adopted this approach. Confirmation of the elevat-
ed CK is advised at least once following a period of 7 days in which the person refrains 
from exercise. Preferably the interval between the two measurements is one month. 
A difference between the algorithms is the priority for forearm exercise testing (see framed 
text) because the American review proposed this as the next step to perform in cases with 
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marked exercise intolerance. If abnormal, metabolic testing for glycogen and lipid storage 
disorders was advised and the mitochondrial respiratory chain enzymes. For the latter, 
respiratory chain enzyme analysis can be performed on fresh or snap-frozen muscle tissue 
in specialized centers.86 Of note, exercise tests will not pick up Pompe’s disease or carnitine 
palmitoyltransferase II (CPT2) deficiency, for which the diagnostic screening tests of choice 
are measurement of acid maltase enzyme activity in leucocytes and tandem mass spec-
trometric measurement of serum/plasma acylcarnitines respectively. In contrast, the EFNS 
guidelines incorporate a diagnostic test for McArdle’s disease in the set of histochemical 
investigations advised for the muscle biopsy specimen. Furthermore, the EFNS stresses 
the importance of enquiring the family history of neuromuscular disorders, familiar hyper-
CKemia or malignant hyperthermia (see framed text).
Both algorithms for asymptomatic and pauci-symptomatic hyperCKemia propose EMG 
studies before taking a muscle biopsy. It was previously reported that the sensitivity of nee-
dle EMG was 69% to pick up abnormalities that correlate with underlying pathology in the 
biopsy specimen and that its specificity was 54%.  The positive predictive value of an EMG 
to predict an abnormal muscle biopsy is only 51% and the negative predictive value of nor-
mal EMG to predict normal biopsy result is 74%.76 Nevertheless, the EFNS guidelines advise 
EMG including nerve conduction studies in all patients with persistent hyperCKemia with-
out further explanation on the usefulness of nerve conduction studies for hyperCKemia. 
Notably, the 25 reported cases with neurogenic diagnoses all had endured a muscle biopsy 
Exercise test for glycogenoses
Exercise tests can demonstrate a defect in glycogenolysis in most muscle glycogenoses (except deficiency of 
acid maltase,106 phosphorylase b kinase or branching enzyme) as ammonia levels increase normally following 
exercise but lactate levels fail to raise because production is reduced or absent. In myoadenylate deaminase 
deficiency lactate levels increase normally but ammonia levels remain at baseline. McArdle described in 1951 
the lack of lactate rise in a patient with myophos phorylase deficiency following ischemic exercise of forearm 
muscles.107 Ischemic exercise bears the risk of necrosis. For detection of McArdle’s disease the non-ischemic 
forearm test is a good alternative for the potentially hazardous ischemic forearm test.108 
Exercise test for mitochondrial myopathy
Venous oxygen desaturation during non-ischemic forearm exercise can be used as diagnostic screening test 
for mitochondrial myopathy(MM). In MM exercise-induced venous O
2
 desaturation was limited compared 
with healthy subjects.109  Notably, both tests are time consuming, requiring some expertise of the executor 
to perform properly. On the other hand a muscle biopsy is, though invasive, a procedure useful for multiple 
purposes as the tissue can be used for histology, histochemistry, immunological studies and even metabolic 
tests and RNA analysis if requested.
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that showed neurogenic atrophy.84 Thus in the majority of reviewed studies the EMG ap-
peared not the primary tool to reveal neurogenic disease. In the EFNS algorithm myopathic 
changes on EMG are used as one of the screening criteria for muscle biopsy. If myopathic 
changes are found this is sufficient reason to take a biopsy independently from the serum 
CK level, symptoms or age. But if EMG is normal in males > 25 years of age without exercise 
related symptoms and serum CK is mildly elevated (< 3 times normal) muscle biopsy is not 
indicated according to the EFNS guidelines. The American review considers the role of the 
EMG to be limited in hyperCKemia, and mainly useful to exclude motor neuron disease and 
myotonic dystrophy. Apparently only needle EMG is required according to this algorithm. 
Resuming, investigation of muscle tissue is indicated in all cases with hyperCKemia, when 
neurogenic or myotonic findings are excluded with an EMG, unless the case is male > 25 
years without exercise related symptoms and having a serum CK < 3 times normal. 
Muscle biopsy according to the EFNS guidelines should include histology (Haematoxylin & 
eosin staining) and histochemistry (Gomori trichome, Oil red O, period acid-schiff, ATP-ase 
(9.4, 4.2 and 4.6), SDH, NADH, cytochrome c oxidase, myophosphorylase, and acid phos-
phatase as well as immunohistochemical studies with antibodies against dystrophin, α, β, 
γ and δ sarcoglycans, dysferlin, caveolin-3, Major histocompability complex 1 (MHC-1) and 
α-dystroglycan.84 The muscle biopsy appearance may also direct further (optional) diag-
nostic tests such as Western Blotting analysis (WB) of muscle tissue as well as enzymology 
(e.g. acid maltase enzyme activity in leucocytes) and mitochondrial DNA analysis. 
In Malignant hyperthermia (MH) patients are asymptomatic during normal daily activities but the condition 
manifests itself during general anaesthesia when the body temperatures raises to very high levels, potentially 
with fatal outcome.110 It is a severe and hazardous condition related to mutations in the RYR1 gene and some-
times also to myopathy with central cores.111, 112 In symptomatic patients and in relatives a positive in vitro con-
tracture test on fresh muscle tissue is used to confirm malignant hyperthermia susceptibility. Only one report has 
reported that 51% of the cases with hyperCKemia had a positive in vitro contracture test.113 In contrast, in other 
studies on idiopathic hyperCKemia malignant hyperthermia susceptibility was found to be a rare condition.89, 114 
Moreover, in the study of Weglinski the majority of the patients with a positive contracture test and asymptom-
atic hyperCKemia did not get complications when they experienced general anaesthesia.113 
Moreover, the consequences of MH testing are not settled and this invasive test is not generally available (e.g. in 
the Netherlands the contracture test is available in one expert center, Canisius-Wilhelmina Hospital in Nijmegen). 
Thus, for practical reasons it is advised that patients with idiopathic hyperCKemia inform their physicians that 
they have a potential risk of MH and that appropriate anaesthetic guidelines should be followed.53, 84
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The American review analysis on muscle tissue shares the previously proposed similar im-
munohistochemical analysis but also includes Western blot analysis of dystrophin, dysfer-
lin, calpain-3, caveolin-3 in the standard work up. Diagnostic tests for Pompe’s disease and 
mitochondrial disorders are not mentioned.
Concerning the likelihood that muscle biopsy and/or EMG resulted in a definitive diagno-
sis was calculated at 28.1% or 125/445 cases in nine studies.53 However, the two diagnostic 
algorithms reviewed in total 11 studies and only one study performed routinely WB anal-
ysis in the work up for hyperCKemia.78 On the other hand studies that focussed on long 
term follow up have found that the prognosis of hyperCKemia was favourable.73, 74 For the 
daily practice it is important to prevent unnecessary diagnostic tests, especially invasive 
procedures like taking a muscle biopsy. As mentioned before, hyperCKemia should be 
defined as values above 1.5 times the upper limit of normal.84 It will increase the specificity 
of the test to screen for neuromuscular disorders with an acceptable reduce in sensitivi-
ty.85 Before the diagnosis idiopathic hyperCKemia is made, careful history taking, including 
family history, neurological examination and diagnostic tests such as muscle biopsy and 
or DNA analysis should be considered to exclude subclinical myopathy.61, 72, 76, 84
The final step in the algorithms is genetic analysis in which the American review advises 
to consider DNA analysis of five muscular dystrophy genes namely dystrophin, dysferlin, 
calpain-3, caveolin-3 and fukutin-related protein (FKPR). Of note, the anoctamine-5 (ANO-
5) gene was not yet mentioned, and neither is suggested in which order DNA analysis of 
the different genes could be performed. Unfortunately the algorithm does not indicate 
whether all undiagnosed cases should receive DNA testing or how elaborate DNA anal-
ysis should be, such as including sequencing of the DMD gene. Remarkably in the EFNS 
guidelines DNA analysis of muscular dystrophy genes is not mentioned except for the 
DMD gene to screen for possible carrier status in females. The EFNS guidelines advise that 
all women with increased CK at any level should receive further work up, first by means 
of DNA analysis of the DMD gene which will detect 70% of the carriers, and, in case no 
mutations are found, by means of a muscle biopsy. 
In patients with asymptomatic or paucisymptomatic hyperCKemia in whom a neuromus-
cular disorder is considered the level of CK in combination with clinical features may help 
to guide diagnostic work up. Neuromuscular diagnoses that can present with hyperCKe-
mia are summarized in a table (Supplementary table, pages 125-133); table A reports the 
CK level and age of onset of the different disorders and table B gives information on spe-
cific weakness patterns, disease progression and expected results of diagnostic tests. The 
main reference for this overview is the neuromuscular home page87; when the information 
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on the various disorders are summarised in a table it is clear that CK levels are reported 
quite differently in the literature: some authors use the absolute measured CK level in 
units per litre, some the level in a ratio to the upper limit of normal (e.g. 15x normal) and 
others prefer a qualitative description like “slightly elevated” or “ very high” CK level. This 
suggests that also laboratory assessments are subject to interpretation; measured levels 
may increase or decrease the probability of a specific disorder they but should be used in 
relation to clinical features in the patient.
Dystrophinopathy in asymptomatic or pauci-symptomatic hyperCKemia
The aforementioned algorithms on asymptomatic or pauci-symptomatic hyperCKemia 
also reported the yield of diagnostic work up in seven series dating from 1988-2008 con-
cerning 348 cases with hyperCKemia of whom 261 were males (75%).72, 76-78, 88-90 Dystro-
phinopathy was confirmed in 17 patients with asymptomatic or pauci-symptomatic hy-
perCKemia and in one carrier. This means that 6.5% of the males was diagnosed with 
dystrophinopathy, which accounted for 14% of all diagnoses in these combined patients 
series. Following polymyositis, dystrophinopathy was the second most frequently con-
firmed diagnosis among the participants in these series. Nevertheless, in 3/17 males (18%) 
with diagnosed dystrophinopathy the biopsy was not conclusive, but the diagnosis was 
confirmed by DNA analysis.76, 78 One of these patients was included in the study where WB 
was performed.78 This indicates that dystrophinopathy should be considered in persistent 
hyperCKemia and, if indeed suspected, diagnostic work up should include immunological 
studies on muscle tissue and/or DNA analysis of the DMD gene.
EMG 
The role of the electromyography (EMG) in the work up for possible dystrophinopathy is 
considered to be limited, and mainly useful to exclude, if clinically relevant, motor neuron 
disease and myotonic dystrophy. Both disorders have a different phenotype, course and 
inheritance than dystrophinopathy but in the first stage they have features in common 
with muscular dystrophy including a mildly elevated serum CK. EMG might distinguish 
the different disorders. Motor neuron disease represents a broad spectrum: the spinal 
muscular atrophies (SMA) which are inherited as an autosomal recessive, X-linked or domi-
nant trait. This in contrast to progressive spinal muscular atrophy (PSMA) and amyotrophic 
lateral sclerosis (ALS) which occur sporadically in ninety percent of the cases. The latter 
two disorders will not be easily confused with an underlying muscular dystrophy because 
the presenting clinical symptom in those is painless weakness, often asymmetrical and 
distally located with atrophy and fasciculations. Hereditary SMA is caused by homozy-
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gous mutations in the SMN1 gene and besides congenital (type 1), infantile (type 2) and 
childhood/juvenile onset (type 3) late onset is described which is classified as SMA type 
4. The clinical features proximal weakness and mildly elevated CK in hereditary SMA types 
3 and 4 may resemble muscular dystrophy and particularly dystrophinopathy in males. 
Other SMA’s with possible limb girdle weakness are Kennedy’s syndrome (X-linked bulbar 
spinal muscular atrophy) and autosomal dominant proximal SMA with adult onset. Fascic-
ulations are often not prominently present and calf muscles have normal size. Neurogenic 
abnormalities on EMG will disclose the underlying neurogenic disorder and this excludes 
dystrophinopathy. However in a study that compared EMG and biopsy results in 114 cases 
with hyperCKemia the biopsy showed 14 cases with neurogenic atrophy.76 In 13 cases 
of this group EMG was available which confirmed neurogenic abnormalities only in five. 
The definite diagnosis was not reported, neither whether genetic tests were performed, 
but this might indicate that a biopsy could be more sensitive to find neurogenic abnor-
malities than EMG in adult onset SMA. However the EMG is expected to be more specific 
and neurogenic abnormalities will direct towards different work up e.g. DNA analysis of 
the SMA genes instead of muscular dystrophy genes. In myotonic dystrophy specific myo-
tonic discharges can be found on needle EMG. The next step will be DNA testing of the 
DMPK gene. If symptomatic, the phenotype in DM1 is often quite typical with myopathic 
face, ptosis, and atrophy of temporal muscles and weakness is more prominent in distally 
located muscles in hands and feet and DM1 will not easily be confused with muscular 
dystrophy with a limb girdle pattern. Asymptomatic or pre-symptomatic family members 
however could present with hyperCKemia. Myotonic dystrophy type 2 (DM2 or proximal 
myotonic myopathy, PROMM) however can present with proximal weakness of the legs 
in which pain is often prominent. Calves can be enlarged as well. An EMG in DM2 will not 
always disclose myotonic discharges, but if these discharges are found this will direct to-
ward DNA analysis of the PROMM gene as the next step.
In conclusion, the benefit of EMG for diagnosis in symptomatic and asymptomatic adult 
patients is probably very limited and mainly aiming at exclusion of the rare disorders SMA 
and DM2. Nevertheless in asymptomatic patients the EFNS guidelines propose an EMG in 
the screening process before the indication of muscle biopsy, with the consequence that 
in case the EMG is normal, a muscle biopsy can be omitted in males > 25 years without ex-
ercise related symptoms in whom the serum CK is only mildly elevated (< 3 times normal). 
Notably, EMG will not contribute to the diagnosis dystrophinopathy and very mild BMD 
cases older than 25 years might be missed because following a normal EMG a muscle 
biopsy is not proposed according to the current European guidelines.
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Figure 1 Muscle biopsy (anterior tibial muscle) of a 4.5 y old boy with DMD
A:   Hematoxylin-Eosin : atrophic and hypertrophic fibers with locally regenerating fibers; endomysial and peri- 
  mysial fibrosis. 
B,C,D: immunohistchemical staining with dystrophin antibodies DYS1 (B), DYS2 (C), DYS3(D): negative, 
  besides one revertant fiber (arrow) E: immunohistochemical staining with spectrin:normal signal 
  (but dystrophic histology). Pictures courtesy dr. S.G. van Duinen
Muscle biopsy
Muscle biopsy in dystrophinopathy has two main goals: to confirm and classify muscular 
dystrophy in undiagnosed sporadic symptomatic patients and to investigate dystrophin 
(semi)quantitatively in patients with a phenotype that seems not concordant with the 
mutation in the DMD gene.
A B
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If DMD is suspected in a young boy the diagnosis can be confirmed either with DNA 
analysis of the DMD gene or immunohistopathologically in muscle tissue from a biopsy 
sample. The advantage of the latter is that the results of histologic and immunological 
investigations often are achieved faster, and in case the clinical features are not typical 
for DMD (and BMD is also considered) immunohistochemistry of biopsy tissue will inform 
about dystrophin expression. The disadvantages is the invasive nature of the procedure 
for which anesthesia is requested in very young children. If the biopsy shows that dys-
trophin is absent, DMD is confirmed. Each muscle specimen is routinely examined his-
topathologically. Typical features in dystrophinopathies are dystrophic features such as 
abnormal variation in muscle fiber size due to atrophic and hypertrophic fibers, inflam-
matory features with focal necrosis and regenerating fibers and extensive fibrosis because 
muscle fibers are replaced by fat and connective tissue (figure 1).91
For diagnostic confirmation immunohistochemical examination with antibodies raised 
against different parts of dystrophin are used. Immunohistochemical analysis of dystro-
phin is a qualitative measure for dystrophin in muscle tissue. In case of DMD dystrophin 
will be absent, although sometimes a minority of the fibers will stain positive. These so-
called revertant fibers are explained by recovery of the reading frame through alternative 
splicing or multiple exon skipping.92
In Becker muscular dystrophy the pathological changes are similar to those found in DMD. 
Based on histopathologically features alone BMD cannot be distinguished from DMD.91 
Usually BMD presents at older age compared to DMD and its progression is slower al-
though pathological changes have been found in very young boys with BMD. 91 In con-
trast to DMD dystrophin is present in muscles of BMD patients but in an aberrant size and/
or reduced amounts. Immunohistochemical investigation with different antibodies (e.g. 
DYS1 against the rod domain, DYS3 against the N-terminus and DYS2 against the Carboxyl 
terminus of dystrophin; figure 2) can show that dystrophin is distributed normally but 
globally reduced or that the staining is discontinuous with either a normal or reduced 
intensity. However, often this test is not sufficient to confirm the diagnosis BMD. Western 
Blot analysis (WB), which is a semi quantitative measurement of dystrophin, can detect 
abnormal amounts of dystrophin and/or dystrophin with a different molecular weight. A 
smaller dystrophin may be caused by deletions of one or more exons or by small muta-
tions and a larger size is found in case of duplications of one of more exons. WB is more 
elaborate and requiring expertise. In the Dutch situation this test is available in one refer-
ence laboratory, the Laboratory for Diagnostic Genome Analysis (LDGA) in Leiden. This 
in contrast to immunohistochemical analysis which is routinely performed in most neu-
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romuscular expert centers. Assessment of dystrophin is not only used in diagnostic work 
up but is also important to evaluate the effect of therapy in clinical DMD trials; especially 
for quantification of low levels of dystrophin several immunohistochemical methods have 
been developed.93-95 Efforts to harmonize dystrophin quantification are ongoing; prelimi-
nary results suggest that different methods to assess dystrophin levels result in compara-
ble results both between different protocols for immunofluorescence and when compar-
ing immunofluorescence and Western blotting.96
In a female DMD carrier immunohistochemical analysis of muscle tissue may show a mo-
saic pattern of dystrophin positive and negative muscle fibres. In asymptomatic carriers 
the sensitivity for immunohistochemistry was only 26%.97 Moreover, DNA analysis is the 
first choice to confirm the carrier status in asymptomatic females as this is non-invasive, 
and genetic diagnosis is necessary if further prenatal testing and counselling is wanted.
Figure 2. Schematic drawing of the dystrophin protein. 
Dystrophin consists of four domains: the N-terminal actin-binding domain (yellow), the central rod domain, which 
contains 24 spectrin like repeats (light blue), interrupted by four hinge regions (dark blue), the cysteine rich domain 
(orange) and the Carboxy-terminal domain (red). The regions of the dystrophin protein which are stained by tdiffer-
ent DYS antibodies  on a muscle sample are marked underneath the cartoon: DYS3, Amino acids 67-713; DYs1 amino 
acids 1181-1388; Dys 2 extreme Carboxy-terminus. Adapted from figure courtesy dr. A. Aartsma-Rus
Discrepancy between mutation and phenotype
In symptomatic patients in whom a mutation in the DMD gene is found the phenotype 
can be non-conclusive, e.g. a child with milder symptoms than expected for DMD or a 
youngster with a more progressive course than expected in BMD. Besides this, mutations 
have been described that can result in phenotype between DMD and BMD and those are 
associated with outliers.29, 30, 98 Also, within one family the same mutation can result in dif-
ferent phenotypes.99 Examination of a muscle specimen can clarify whether dystrophin is 
absent or present and in the latter case subsequently WB can detect the abnormal size and/
or amounts of dystrophin, compatible with BMD or with intermediate dystrophinopathy.
N-terminal actin 
binding domain
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Resuming, from a clinicians viewpoint the role of a muscle biopsy is a diagnostic tool in 
the following instances: 1) sporadic cases in whom dystrophinopathy is suspected but DNA 
analysis has not revealed a mutation, 2) in patients in whom the mutation is not conclusive 
in relation to the phenotype and 3) in adult patients with mild symptoms in whom the 
differential diagnosis is large and histopathological and/or immunological classification on 
muscle tissue may guide subsequent DNA requests. In male patients with possible BMD 
additional Western Blotting could be considered. In female patients sporadic symptomatic 
carrier status can be detected by immunohistochemical staining with dystrophin antibodies 
of the muscle biopsy.
 
DNa analysis
The DMD gene is the largest human gene, located on the X-chromosome, and consists 
of 79 exons. Large re-arrangements in de DMD gene account for 70% of the DMD mu-
tations and can be detected by means of several techniques such as Southern blotting, 
Multiplex-PCR or nowadays Multiple Ligation-dependant Probe Amplification (MLPA) 
which is more accurate, faster and cheaper.100, 101 Approximately 60% of the patients has 
a deletion of one of more exons, and in 5-10 % of the BMD/DMD patients duplications 
are found.11 The reading frame hypothesis explains that large deletions can result in mild 
BMD whereas a deletion of one exon can result the more severe phenotype DMD.102 In 
patients with dystrophinopathy in whom no deletion or duplication was found, sequenc-
ing techniques can be performed to search for small mutations. Small mutations can re-
sult in direct stops (nonsense mutations), truncating frameshifts, amino acid substitutions 
(missense and neutral mutations), or affect splicing.101 However, sequencing of the large 
DMD gene is laborious and mutations in the promoter area and deep intronic mutations 
that may affect splicing will not be detected. Consequently, in 2-5% of symptomatic cas-
es with DMD no mutation can be found. If no mutation in the DMD gene can be found 
in genomic DNA of the patient or if it is uncertain whether a mutation is pathogenic, 
RNA studies can be performed to give information about the status of the mutation.103, 104 
Novel mutations and unique variants can be registered at the DMD/BMD database that 
collects observed mutations from all over the world including the accompanying pheno-
type DMD or BMD (www.dmd.nl). DNA analysis of the DMD gene can serve multiple goals: 
as initial minimally invasive diagnostic tool in sporadic symptomatic patients to confirm 
the diagnosis dystrophinopathy or to detect the mutation if muscle biopsy analysis has 
revealed dystrophinopathy. Notably, for future treatment options like exon-skipping it is 
important to know the exact boundaries of the deletions found.105 In familial cases DNA 
analysis will be the first choice and can replace muscle biopsy if the mutation is known. 
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Furthermore, DNA analysis is used to investigate carrier status in female family members 
and for prenatal testing. In daily practice results of DNA analysis usually take some time. 
Screening for deletions or duplications is the standard procedure which regularly takes a 
few weeks. Sequencing of the whole gene and its interpretation is more time consum-
ing and results may take several weeks. Resuming, molecular-genetic diagnosis is the 
mainstay in the diagnostic work up of dystrophinopathies, because information about 
the mutation is important to improve classification for individual patients, to offer genetic 
counseling of family members and hopefully also to guide future therapies in DMD.
 
aim of this thesis
This thesis focuses on heterogeneous clinical aspects of dystrophinopathies. The follow-
ing topics have been investigated:
Becker muscular dystrophy
Diagnosis and phenotype
The phenotype of BMD may vary from severe muscle weakness with cardiomyopathy and 
early death to exercise induced myalgia and/or muscle cramps associated with hyperCKe-
mia. Since 1983 genetic analysis was available in the Netherlands, which started with link-
age analysis  in BMD and DMD families. After the cloning of the DMD gene in 1986 and the 
identification of dystrophin in 1987 it became clear that dystrophinopathy in the majority 
(70%) of the patients was caused by large rearrangements like deletions or duplications 
of one or more exons.10, 115, 116 Small mutations in the large DMD gene probably cause the 
disorder in the remaining one-third of the patients and novel techniques to find these 
mutations became available much later.117, 118 It is therefore possible that DNA diagnosis in 
D/BMD patients with small mutations has not been made if they had been referred for DNA 
analysis in the period before sequencing techniques could be used to screen for small mu-
tations. We were interested whether it was worthy to re-analyse the DNA of patients with 
potential BMD but without a genetic diagnosis yet. The results of this study are presented 
in chapter 2.
The phenotype of BMD patients with specific mutations encompassing exon 51 is inter-
esting concerning treatment of boys with DMD with exon-skip therapy.105 The dystrophin 
product within the muscles of these BMD patients is the expected end product following 
successful exon-skip therapy in boys with DMD. Chapter 3 describes the phenotypes of 
three Dutch BMD patients from two families who have  in-frame deletions including exon 51.




Imaging of the brain: morphology of the brain and the relation to cognition
Approximately 30% of DMD patients have learning and/or behavioral problems. Full length 
dystrophin which is essential for normal muscle function is also present in brain tissue al-
though its function in brain tissue is not known. Besides, several dystrophin isoforms are 
expressed in normal brain (figure 3). Dependent on the location of the mutation in the 
DMD gene in DMD dystrophin isoforms are expected to be present or absent.119, 120 Neu-
ropsychological studies in DMD patients have shown a relation between cognitive scores 
and the location of the mutation; DMD patients with a mutation downstream of exon 44 
have a lower IQ and a higher risk of ADHD compared to patients with a mutation upstream 
of exon 44.46, 50, 120, 121 Chapter 4 describes quantitative results of an explorative MRI study on 
brain morphology and microstructure in DMD. 
Imaging of the brain: morphology of the skull
Enlargement of the calves in dystrophinopathy is often an early and prominent feature 
which was already described by Guillaume Duchenne in his observations on DMD in 1868. 
This enlargement represents muscle hypertrophy and it is known that during progressive 
clinical stages the muscle tissue is replaced by fat and connective tissue. Also other muscle 
groups can be hypertrophic like deltoid muscles and the tongue. In a MRI study of the 
brain, which we performed in DMD boys aged 8-16 years and age-matched healthy con-
trols, we observed on the transverse images of the head that hypertrophy of the temporal 
muscles was present in all boys with DMD and that the shape of their skulls was rounder. 
Chapter 5 illustrates these features and presents quantified results. 
Early prednisone treatment for Duchenne muscular dystrophy 
in the Netherlands 
Steroid treatment extends the ambulant phase in DMD.122, 123 In natural cohort studies boys 
with DMD became wheelchair-bound between 10-12 years.124 Since the introduction of 
chronic steroid treatment in the mid 1990’s the age of ambulation has improved with at 
least one year. The benefit depends on the dosage and age at which steroids are started. 
In the Netherlands guidelines for prednisone treatment were established in 2004.123 In the 
rehabilitation center De Trappenberg, however, young boys with DMD have been offered 
prednisone since 1996 in an intermittent  scheme, in which 10 days prednisone 0.75 mg/kg 
per day was alternated with 10 days without corticosteroids. The study presented in chap-
ter 6 retrospectively evaluated long term follow up of steroid treatment in a cohort of 35 
DMD patients and results are compared with the literature..
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Figure 3  Dystrophin and its isoforms  
Adapted from figure courtesy dr. A. Aartsma-Rus
N-terminal actin 
binding domain







Isoforms and the corresponding tissues where the  
isoforms are expressed 
Dp427c: Cortical neurons; skeletal and cardiac muscle 
Dp427m: Skeletal and cardiac muscle; glial cells 
Dp427p: Purkinje cerebellar neurons; (skeletal muscle) 
Dp260: Retina; (brain and heart) 
Dp140: Brain; kidney 
Dp116: Swann cells 
Dp71: Brain; liver; cardiac muscle; 
Dp40: Ubiquitous
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Part 1 / Chapter 2
abstract 
Introduction 
The phenotype of Becker muscular dystrophy (BMD) is highly variable, and the dis-
ease might be underdiagnosed. We searched for new mutations in the DMD gene 
in a cohort of previously undiagnosed cases who had been referred in the period 
1985-1995. 
Methods
All requests for DNA analysis of the DMD gene in probands with suspected BMD were 
re-evaluated. If the phenotype was compatible with BMD, and no deletions or dupli-
cations were detected, DNA samples were screened for small mutations. 
Results
In 79 of 185 referrals no mutation had been found. Analysis could be performed on 31 
DNA samples. Eight different mutations, including four novel ones, were found. Long 
term clinical follow-up is described. 
Conclusion
Refining DNA analysis in previously undiagnosed cases can identify mutations in the 
DMD gene and confirm the diagnosis BMD genetically. A delayed diagnosis can still 
be valuable for the proband or the relatives of BMD patients. 
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Introduction
The phenotype of Becker Muscular Dystrophy (BMD) was first described in 1955 as a ju-
venile or benign type of X-linked muscular dystrophy.8, 129, 130 The symptoms are similar 
to those of Duchenne Muscular Dystrophy (DMD) but the onset is later and the progres-
sion is slower. Moreover, BMD is characterized by a large phenotypical variability, rang-
ing from severe muscle weakness with cardiomyopathy and early death to exercise-in-
duced myalgia and/or muscle cramps associated with hyperCKemia.13, 80, 131 In addition, 
severe cardiomyopathy has been found in patients with BMD without skeletal muscle 
weakness.132 The diagnosis is supported by an X-linked inheritance pattern as well as by 
hypertrophy of the calves and increased serum creatine kinase (CK) activity, although nei-
ther of the last two features is pathognomonic for dystrophinopathy.17, 53 The mean age 
at which muscle symptoms are noticed in BMD patients is 11.2 years (with a range of 10 
months to 38 years) whereas the mean age at diagnosis is 17.7 years;24 however, late onset 
in the 3rd-7th decade has been reported.27 This indicates that diagnosis is often delayed. 
The gold standard for confirming BMD in adult males is molecular-genetically by DNA 
analysis of the DMD gene.106 For a long time, following the cloning of the DMD gene in 
1986, DNA analysis of this gene was the first and only test available to patients suffer-
ing from a muscular dystrophy.10, 107 DNA analysis for other forms of muscular dystrophy 
became available years later, and these are classified as Limb Girdle Muscular Dystrophy 
(LGMD) with a growing number of subtypes.133, 134 
In the Netherlands, DNA analysis for dystrophinopathies and limb girdle muscular dystro-
phies is performed in one referral laboratory, the Laboratory for Diagnostics and Genome 
Analysis (LDGA) at the Leiden University Medical Center. Seventy percent of the patients 
with a dystrophinopathy have deletions or duplications in the DMD gene, which can be 
detected by several techniques of which Multiple Ligation-dependant Probe Amplifica-
tion (MLPA) is currently the most accurate.100, 101 In the last decade new techniques have 
been developed for the detection of small mutations in the DMD gene; from 2008 until 
2012 pre-sequencing techniques such as High Resolution Melting Curve Analysis (HC-
MCA)135 were a practical method to screen for small mutations whereas currently direct 
sequencing is used in regular patient care.
In the present study we have investigated whether BMD had been underdiagnosed in the 
early decade of DNA analysis and, if so, to see if we could improve the diagnostic yield by 
applying newer techniques; we have reviewed the genetically undiagnosed cases among 
patients referred for suspected BMD in the period 1985-1995.
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Methods
In 2011, we scrutinized the BMD database of the LDGA for files of patients referred in the 
period 1985-1995. Besides the initial application form for DNA analysis of the proband, 
these files may include a family tree, data of family members, results of other investiga-
tions performed and information on the clinical follow up. To improve the yield of diag-
nostic procedures at the LDGA, the stored DNA samples are often re-analysed if a new 
technique becomes available. One of us (CS) re-examined the files of all male probands in 
whom no deletions or duplications of one or more exons had been found with Southern 
blot analysis or the MLPA technique. For our study we included only those patients whose 
phenotype was considered compatible with BMD: male patients with hyperCKemia and 
proximal weakness, myalgia, cramps and / or calf hypertrophy. Patients that did not fulfil 
these criteria were categorised as unlikely BMD and were excluded. Referrals of patients 
known to be deceased at time of re-evaluation were included if the finding of a new mu-
tation would have consequences for counselling of female family members. Referrals from 
abroad, which had no follow-up information, were also excluded.
DNA from patients was re-analysed, if still available, by means of MLPA analysis if only 
Southern blot technique was used in the past, which was the case in around 40% of the 
patients. Subsequently, in all patients in whom no large deletions or duplications had 
been found, the DNA was screened for small mutations by means of HR-MCA followed by 
sequence analysis.135 All newly identified mutations were reported to the referring physi-
cian and to the patient and/or his family. If possible, the patient or family members were 
approached for a new blood sample to confirm the mutation. 
results
In the period 1985-1995, blood samples from 185 male patients suspected of having BMD 
were sent to the LDGA for DNA analysis of the DMD gene. In the period between 1995 
and 2011 a genetic mutation had been found in 106 patients (Figure 1), in 79 cases in the 
DMD gene and in 27 cases in other genes (Table 1). We reviewed the files of the remaining 
79 probands. Of these, 42 cases were excluded because the patients were deceased, the 
referral had been received from abroad, the clinical information was insufficient or the 
clinical information was incompatible with the diagnosis of dystrophinopathy (Figure 1).
The remaining 37 probands were considered candidates for renewed diagnostic testing 
for BMD (Figure 1), but in six probands no DNA was left. Thus, further DNA analysis could 
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Figure 1  Flow diagram of the selection process of patients, referred for 
   suspected BMD between 1985-1995, who were eligible for
   re-analysis of the DMD gene. 
BMD: Becker muscular dystrophy; HR-MCA: High Resolution Melting Curve Analysis; MLPA: Multiple Ligation-depen-
dant Probe Amplification. Mutation in bold: novel mutation
Between 1985-2011:
79   mutations found in the DMD gene 
• 59  deletions
• 10  duplications
• 10  small mutations
27   mutations found in other genes
42 Excluded
• 5  cases known to be deceased,    
counseling not meaningful
• 3  referrals received from abroad
• 22  insufficient clinical data 
• 12  clinical data not suggestive of BMD
• 4 neurogenic features reported
• 3 not X-linked
• 3  involvement CNS
• 1 distal weakness
• 1 necrotizing myopathy
185  applications  for BMD in 
1985-1995
79 files re-evaluated in present   
study




DNA analysis of the DMD gene by HR-
MCA  and sequencing (n=28)
5 mutations found
• exon 25;  c.3337C>T, p.Gln1113*
• exon 71;  c.10258del, 
p.Ser3420Leufs*25
• exon   6; c.482-484del, p.Thr161del 
• exon 21; c.2623-2A>C; somatic 
mosaicism 
• exon 60; c.8974G>A, p.Val2992Met
DNA analysis of the DMD gene 
by MLPA (n=14) 
3 mutations found
• deletion exons 3-4
• duplication exon 2
• deletion exons 8-15; 
somatic mosaicism 
be performed in 31 probands. In 14 cases we performed MLPA analysis, showing an in-
frame deletion of exon 3-4 (no. 1), a duplication of exon 2 (no. 2), and a somatic mosaic 
frameshift deletion of exon 8-15 corresponding to a previously detected mosaic dystro-
phin pattern in muscle tissue (no. 3)(Table 2). The DMD gene of the remaining 28 probands 
was analysed by HR-MCA and sequencing. Small mutations in the DMD gene were found 
in five patients (Table 2). Four of these are novel mutations and considered pathogenic 
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in three patients: a frameshift mutation in exon 71 (c.10258del, p.ser3420Leufs25*; no. 4), 
a mosaic splice-site mutation of exon 21 (c.2623-2A>C; no. 5) and a 3-basepair deletion 
in exon 6 (c.482-484del, p.Thr161del; no. 6) which was not previously reported in the lit-
erature although submitted in Leiden Muscular Dystrophy pages database in both one 
DMD and two BMD patients. The fourth novel mutation is a missense mutation in exon 60 
(c.8974G>A, p.Val2992Met; no.7); in silico analysis does not predict to affect splicing of this 
exon. However, the amino acid valine is evolutionary highly conserved in codon 2992 and 
previously dystrophin amounts were found to be reduced in muscle tissue of this patient. 
This variant has not been reported before in literature, the Muscular Dystrophy pages of 
the Leiden Open Variation Database (LOVD) or the Human Gene Mutation Database. 
Finally, a nonsense mutation was found in exon 25 (c.3337C>T, p.Gln1333*) and the severe 
BMD phenotype of patient no. 8 might be explained by exon skipping of this “in-frame” 
exon.99 However, there was no muscle tissue available for RNA analysis. This mutation in-
deed has been reported in patients with BMD and DMD/BMD phenotypes in the LOVD.
Clinical data of the eight patients with a newly detected mutation are presented in Table 
2. All patients with a novel mutation (nos. 4,5,6,7) were alive and three of them (nos.4,6 and 
7) agreed to undergo a new clinical assessment. Patient no. 4 with a frameshift mutation in 
exon 71 had a severe BMD phenotype with normal cognitive development; this mutation 
has not been reported in the LOVD. Frameshift mutations in exon 71 have been described in 
TABle 1:  Diagnoses confirmed by DNa mutation in 185 patients from the 
   diagnostic BMD cohort 1985-1995
gene disorder all (n) %
DMD Dystrophinopathy 87 47,0%
CAPN3 LGMD 2A 7 3,8%
DYSF LGMD 2B 2 1,1%
SGCA LGMD 2D 3 1,6%
FKPR LGMD 2I 2 1,1%
ANO5 LGMD 2L 10 5,4%
SMN1 SMA late onset 2 1,1%
GAA Pompe's disease late onset 1 0,5%
confirmed total 114 62%
 from present study 8 7,0%
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two BMD patients after RNA studies identified two different isoforms of which one was an in-
frame transcript lacking exon 71.136 However, muscle tissue of patient no. 4 was not available 
for RNA studies. Patient no. 5, who was a somatic mosaic for an acceptor splice-site mutation 
(c.2623-2A>C) of exon 21, declined clinical follow up. He was interviewed by telephone and 
said that he had no symptoms at age 23, that he was working full time in the military service 
and playing sports several times a week. Patient no. 7, with a missense mutation, had very 
mild symptoms, calf hypertrophy and hyperCKemia. He had suffered from frequent cramps 
in his teens and as an adult he cannot keep up with his peers in sports. Because his mutation 
is not classified yet as pathogenic for BMD and in the past the working diagnosis of his refer-
ring physician included Miyoshi-type muscular dystrophy (MMD), further DNA analysis was 
performed; no mutations in the ANO5 gene were found. His phenotype is compatible with 
mild BMD and therefore we advised long term cardiac monitoring.
Three patients were deceased and counselling could be meaningful for family members. 
The daughter of patient no. 1 had already requested a test for carrier status in 1985 and 
re-analysis of her DNA confirmed that she was a carrier of the same deletion; now, her 
daughter could be counselled for carrier status. The second deceased patient (no. 8) died 
at the age of 39 from acute cardiac failure and severe cardiomyopathy was confirmed by 
autopsy. Although he had a phenotype of severe BMD with progressive weakness since 
the age of six, he had not had recent clinical follow up by a cardiologist. He did not have 
children and renewed counselling of his sisters was not considered meaningful, as earlier 
linkage analysis had excluded them as carriers. The third deceased patient (no. 3) had a se-
vere cardiomyopathy and died at age 61 from acute cardiac death. Because he was a somatic 
mosaic for a frameshift deletion of exon 8-15 his daughters are at risk to transmit DMD to 
their (grand) sons. Thus genetic counselling and cardiac monitoring is meaningful for his 
female offspring. Finally, counselling was advised for female family members of patient no. 
2 in whom we found a duplication of exon 2, compatible with his severe BMD phenotype. 
New mutations were confirmed in new blood samples in four patients and in the daugh-
ter of a deceased patient. One patient declined sending a new blood sample and two 
other patients were deceased. 
Resuming, in this study we found a mutation in eight of the 31 patients (26%) whose DNA 
was re-analysed. Overall a genetic mutation was found in 114 of the 185 patients who were 
referred in the period 1985-1995 (Table 1). Confirmation of the diagnosis dystrophinopathy 
in eight patients in the present study has improved the diagnostic yield by about 7%. 
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Discussion
Our recent re-evaluation of 79 referrals for DNA analysis of the DMD gene in cases without 
a genetic diagnosis enabled more specific genetic testing in 31 patients and revealed 
mutations in eight patients, at least three of these are novel pathogenic mutations. We 
have described the clinical characteristics with long term follow up of all eight, including 
the patient with a missense mutation with very mild symptoms and hyperCKemia, which 
are compatible with mild BMD. Our findings had relevant clinical implications as we were 
able to advise the patients to undergo screening for cardiomyopathy and could counsel 
the family members. It is surprising that none of these eight patients had visited a neu-
romuscular specialist in all these years, although three of the five patients who are still 
alive had progressive muscle weakness. Apparently their treating rehabilitation physician, 
cardiologist or pulmonologist had not realised that the disorder had not been confirmed 
by a genetic test. A confirmed genetic diagnosis in patients with progressive weakness 
will enable the treating physicians to employ targeted patient care and to offer genetic 
counselling to family members. Cardiomyopathy associated with a mutation in the DMD 
gene can present at a later age.137 Thus confirmation of dystrophinopathy can result in 
early diagnosis of cardiac manifestation and subsequent treatment. 
Renewed DNA analysis based on a requisition form sent in 15-25 years ago has not been 
described before. Whereas the aim of our study was to investigate undiagnosed cases of 
suspected BMD, other studies have focused on searching for small mutations after dystroph-
inopathy had already been proven but genetic classification had not yet been achieved.138, 139 
The present study has some limitations. Firstly, the retrospective evaluation was based on 
clinical data that were collected a long time ago. In the period 1985-1995 DNA analysis was 
the only possibility for confirming a BMD-like phenotype in male adults; little was known 
about limb girdle muscular dystrophies which, as we know now, encompass a broad clinical 
spectrum.134 We therefore confined ourselves to re-evaluating only the DMD gene because 
recalling all unsolved cases for clinical follow up decades after the request for DNA analysis 
was not practically feasible. One exception was made for the patient who agreed in reas-
sessment after we had found a missense mutation; we thought it was in his interest to ex-
clude MMD type 3. Another limitation is that 22 files were excluded because no clinical data 
were available. This shows that sufficient and adequate clinical information provided with 
the request for DNA analysis can help in elucidating diagnoses even after a long time. Finally, 
screening for deletions/duplications and subsequently sequencing for small mutations with 
regular methods does not reveal all BMD mutations, in particular those in the promoter area 
and deep in the introns. RNA analysis on muscle tissue could be helpful in probable BMD 
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cases with abnormal dystrophin expression in muscle tissue or in BMD patients with frame-
shift or nonsense mutations like patients no. 4 and no. 8 respectively in this study. However, 
muscle tissue was not available (anymore) for most of the cases in this study.
The clinical features of some neuromuscular disorders may show similarities to those of 
BMD.19, 21 At the time of our chosen cohort, DNA analysis of the DMD gene was the only 
genetic analysis available to distinguish BMD from sporadic or autosomal recessive LGMD, 
late onset Pompe’s disease or late onset spinal muscular atrophy (SMA). At present, clini-
cians consider a broad spectrum of muscular dystrophies in the diagnostic work up.140 
Indeed, over time other diagnoses were assigned to 27 patients. 
For an efficient diagnostic process it is important that sufficient and standardised clinical 
information is supplied on the requisition form for DNA analysis. This enables the mo-
lecular geneticist to advice on further diagnostic steps to be followed. Next generation 
sequencing (NGS), which is upcoming in regular patient care, is for now not a first choice 
diagnostic tool in suspected BMD as the majority of patients with dystrophinopathy has 
large deletions in the DMD gene; therefore sequencing should follow screening the DMD 
gene for large rearrangements. Regarding adult patients with mild muscle symptoms, re-
ferring physicians should clarify whether diagnostic work up should start with screening 
for deletions or duplications in the DMD gene or with targeted limb girdle gene panels. A 
prospective study could help to support a practical diagnostic strategy for daily practice 
in neuromuscular patient care.
We conclude that extending the analysis by sequencing the DMD gene in potential cases 
of BMD has yielded new mutations in a small but relevant number of patients. The diagnosis 
of dystrophinopathy was confirmed also in patients with mild symptoms at initial referral. 
This had clinical implications with regard to cardiac monitoring and genetic counselling. 
TABle 2  Clinical information on patients with a mutation in the DMD gene 
   found in the present study  p. 44-45 >>
?: Information not available; CK: serum creatine kinase; *) results of Western blot analysis on muscle tissue, as report-
ed in 1992; mutation in bold: novel 
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abstract
Theoretically, 13 % of patients with Duchenne muscular dystrophy may benefit from 
antisense-mediated skipping of exon 51 to restore the reading frame, which results 
in the production of a shortened dystrophin protein. We give a detailed description 
with longitudinal follow up of three patients with Becker muscular dystrophy with 
in-frame deletions in the DMD gene encompassing exon 51. Their internally deleted, 
but essentially functional, dystrophins are identical to those that are expected as end 
products in DMD patients treated with the exon 51 skipping therapy. The mild phe-
notype encourages further development of exon 51 skipping therapy.
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Introduction
Mutations in the dystrophin-encoding DMD gene on the X chromosome result generally 
in Duchenne muscular dystrophy (DMD) if the mutation is out-of-frame and in Becker 
muscular dystrophy (BMD) if the mutation preserves the translational reading frame. In 
BMD patients an altered form of dystrophin is present, whereas in DMD patients dystro-
phin is virtually absent in muscle fibers. Absence of dystrophin in a muscle biopsy has an 
unfavorable prognosis, as DMD patients become wheelchair bound before the age of 13. 
The clinical phenotype in BMD is milder with a large variation in clinical severity.
Currently, new therapeutic strategies, such as antisense-mediated exon skipping, are in an 
early phase of clinical trials and have the potential to change the course of the DMD dis-
ease dramatically. In our recent study, intramuscular injection of an antisense oligonucle-
otide (AON) induced skipping of exon 51 and restored the disrupted open reading frame 
and therefore the production of dystrophin in four DMD patients with deletions of exons 
48-50, 49-50, 50 and 52 respectively.105 Clinical trials with systemic administration of AON 
are taking place. If successful, therapeutic skipping using an AON that targets exon 51 can 
stop further muscle wasting, resulting in a clinical phenotype like BMD. This AON can be 
applied in about 13 % of the DMD patients141. Therefore, focusing on the functionality of 
the probable end product through studying corresponding Becker phenotypes is useful 
and will provide information for patients eligible for this new therapy. This would concern 
the in-frame deletions of exon 45-51, 47-51, 48-51, 49-51, 50-51, 51-52, 51-58, 51-61 and 51-63 
that all are predicted to result in a BMD phenotype.
We describe the clinical phenotype in two BMD pedigrees in the Netherlands carrying de-
letions including exon 51. We also provide a review of BMD patients with these deletions 
reported in the literature. 
Patients and Methods
Methods: 
Since the availability of DNA diagnostics in 1984, more than 1500 Dutch DMD/BMD fami-
lies have been tested in our laboratory. The laboratory database was searched to find pa-
tients with in-frame deletions including exon 51. After obtaining informed consent, data 
on clinical history and neurological examinations were extracted from clinical files and/or 
obtained directly from the patients by the authors (CS and AH-E).
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Data from additional patients were collected by searching the literature and by consult-
ing the international DMD database at the Leiden Muscular Dystrophy pages (http://www.
DMD.nl).142 Where ever possible, additional information was obtained from the authors 
who have published since 1993 on patients with either a deletion of exon 45-51 or of exon 
50-51 and submitted to the database.
results
Description of Dutch pedigrees.
In the Dutch population we found one pedigree with a deletion of exons 45-51 and one 
with a deletion of exons 50-51. Up until February 2009 no Dutch BMD patients had been reg-
istered with in-frame deletion of the exons 47-51, 48-51, 49-51, 51-52, 51-58, 51-61 and 51-63. 
Family 1: deletion exons 45-51
Patient A1, born in 1962, had suffered from painful muscle cramps in his legs since child-
hood. Cramps were mostly provoked by exercise such as hiking or occurred after he had 
bumped his leg. Cramps resulted in painful nodules and could last for one and a half hour. 
Sometimes his father had to carry him home from school. He did not participate in sports 
and did not like running. Neurological examination at the age of 14 showed no muscle 
weakness. A biopsy of the quadriceps muscle at this time showed dystrophic features, 
with groups of necrotic fibers and groups of regenerating fibers as well as local increase 
of endomysial fibrous connective tissue. In 1990 Western blotting showed a slightly re-
duced amount of dystrophin with a smaller molecular weight. DNA analysis identified an 
in-frame deletion of exons 45-51 in the DMD gene and confirmed the diagnosis of BMD. 
He now works as a truck driver and rarely suffers from cramps and is not limited in his daily 
activities, although he avoids jumping from his truck or climbing more than two stairs.
In childhood he had trouble concentrating, was hyperactive and attended a primary 
school for children with educational problems. Subsequently he succeeded in obtaining 
a certificate from a regular technical school. 
A neurological examination in 2008 was unremarkable except for calf hypertrophy. His 
creatine kinase (CK) which had increased 50-fold in 1976 was only marginally increased in 
2008 (243 with a reference value up to 200 U/l). Cardiac examination including echocar-
diography showed no abnormalities. MRI showed normal aspect of the shoulder muscles 
and the muscles of the leg. There were minimal fatty changes in the hip extensors (figure 1).
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His maternal grandfather (patient A2), born 1913 and deceased 1993, carried the same 
mutation. He too had suffered from cramps in childhood and adolescence. At the age of 
78 he was examined by the late Prof. H.F.M. Busch, neurologist. The grandfather showed 
no neurological signs or symptoms of BMD and his CK values were normal. 
Figure 1: MrI images of the muscles in patient a1 
MRI axial T1-weighted images of the muscles in patient A1 at age 46 shows at the level of (A) the shoulder: normal 
volume and signal intensity of the muscles, (B) the hip joint: minimal fatty changes in the gluteal muscles (arrows), 
(C) upper leg: normal volume and signal intensity of the muscles and (D) lower leg: normal volume and signal in-
tensity of the muscles.
Family 2: deletion exons 50-51
Patient B1, born in 1994, visited a pediatrician at the age of 8 because of hyperactive be-
havior. His past history was unremarkable including normal motor milestones; he was able 
to walk unsupported at the age of 18 months. Routine laboratory examination revealed 
increased transaminases and subsequently 8-fold increase in CK. Neurological examina-
tion in 2003 was unremarkable. DNA analysis showed an in-frame deletion of exons 50-51 
in the DMD gene. 
In 2008 he sporadically suffered from muscle cramps but did not complain about mus-
cle weakness. He cycled to school every day for more than an hour each way, including 
riding uphill. He enjoyed climbing trees to help with pruning the branches, and played in 
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a soccer team. Neurological examination showed normal muscle strength. There was no 
calf hypertrophy. ECG and echocardiography were normal. His mean time on a timed run 
test of 10 meters was 2.6 sec, (reference: mean time to run 9 meters for healthy boys of 11 
years is 2.5 ± 0.28 sec).143
Behavior problems were diagnosed as attention deficit hyperactivity disorder (ADHD) 
by a child psychiatrist. Cognitive tests showed a subnormal IQ of 80 with performance 
IQ lower (77) than verbal IQ (90). For hyperactivity he was treated with methylphenidate 
(Ritalin) 54 mg/day, 5 days a week. He attended a primary school for special education. 
He now follows regular secondary education. He is still hyperactive during the weekend 
when he is off methylphenidate. His mother carries the same BMD mutation. He has a 
healthy brother, born 1992, who has not been tested.
Patients from the DMD database at the Leiden Muscular Dystrophy pages and from 
published reports 
The DMD gene variant database at the “Leiden Muscular Dystrophy pages, http://www.
DMD.nl”142 is a public repository of variants reported in literature or submitted directly to 
the database. We used this valuable resource to trace 57 patients with a deletion of exons 
45-51 or 50-51, including our three patients. On February 3rd 2009 the DMD database list-
ed 27 entries with a deletion of exons 45-51 (including 50 patients) and six entries with a 
deletion of exons 50-51(7 patients); 21 of the 33 submissions were from published reports. 
After contacting the authors, seven patients were excluded for further analysis; in two 
patients further testing with MLPA (Multiplex Ligation-dependant Probe Amplification) re-
fined the mutations originally detected by PCR to deletions of exons 45-54 and 49-51. One 
submitter reported that two patients could not be traced back in his local database. Fur-
thermore, two patients were excluded because they appeared to have a Duchenne phe-
notype; their genotype was tested with multiplex PCR and might be not reliable enough. 
One submission appeared to be a monozygotic twin. All new findings were reported to 
the DMD database and used to update the records. In summary, 50 patients were traced 
using the information in the DMD gene variant database.
Our literature search identified twelve more patients: six with deletions of exons 45-51144-146 
and six with deletion exons 50-51 in the literature.147, 148
We made an overview of the 19 patients of whom we obtained clinical information (tables 
1 and 2). These 19 BMD patients came from 12 families. For 43 patients no further informa-
tion was available.
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78 78 cramps normal  M-PCR  patient A2 
present study




1700 M-PCR dystrophin 
present
146
A4 ↑CK 8 8 no 2950 normal M-PCR dystrophin 
present
145
A5 cousin of 
patient A4
7 7 no 896 normal 145
A6 grandfather 
patient 4
67 67 no 63 normal   145
A7 pain on 
exercise
8 8 pain, mild calf 
hypertrophy
1000 normal M-PCR dystrophin 
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Discussion
Our study shows that BMD patients with 45-51 or 50-51 in-frame mutations have a mild 
phenotype.
The clinical phenotype of the three Dutch patients, including the grandfather shows cer-
tain similarities. The course of the disease is mild with muscle cramps without muscle 
weakness and hyper-CK-emia being the main features. As adults these patients showed 
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no clear evidence of progression of the disease with age. None of the patients experi-
enced major limitations in daily life. Intolerance to exercise appears to restrict patient A1. 
Although both patients A1 and B1 have had behavioral or attention problems at primary 
school, they attended regular secondary school and patient A1 functions normally as an 
adult. Behavioral and attention problems appear to occur more frequently in boys with 
Becker muscular dystrophy than in the general population.51 
Also the patients reported in the literature had a mild course of the disease. At older age 
they did not show any symptoms of BMD and had a normal result of cardiac examina-
tion.145, 147The low prevalence of known in-frame mutations encompassing exon 51 in the 
Dutch population could well be an underestimation. Patients with a comparable mild 
phenotype as the ones we have described might not have been recognized as a possible 
BMD and may never have visited a neurologist or a pediatrician. 
Our study clearly shows that previous publications are not always correct regarding the 
extent of the deletions reported. Until recently deletions were mainly detected using 
methods like Southern blotting, multiplex-PCR (Chamberlain and Beggs sets150, 151 and 
quantitative multiplex PCR. MLPA152 is much more accurate and ideally should be used to 
confirm the deletions and, more importantly regarding clinical outcome, to reliably deter-
mine its boundaries. Furthermore, only analysis at RNA level will be able to confirm that 
the translational reading frame remains intact.
It should be noted that the public availability of the DMD database was an enormous 
help for our study. It gave a clear overview of the findings thus far and an easy resource to 
contact the groups having patients of interest. Of course it is unfortunate that not all data 
reported are correct, but the database itself is not to blame for this. To support the data-
base we immediately reported additions and inconsistencies for inclusion or correction.
Gathering information about the phenotype of BMD patients has become relevant now 
that exon skipping therapies are being developed for DMD patients. Since exon skipping 
is mutation specific, each specific exon skip will result in a different shortened variant of 
dystrophin. Therefore, information on the best target exon for individual DMD patients 
may be found by examining BMD patients with different dystrophin variants. Since the 
first clinical trials are aimed at skipping exon 51, we have focused on BMD patients with a 
mutation encompassing this region. In fact, one of the DMD patients that was treated in 
the first human exon skipping trial105 had a deletion of exon 50. After local treatment with 
antisense PRO051 the reading frame was restored and he produced dystrophin which 
should be similar to the dystrophin of patient B1 in our study. This demonstrates how one 
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exon makes the difference between being wheelchair bound at age 9 or climbing trees 
at age 14. The ultimate goal is to develop specific treatments that restore dystrophin pro-
duction in DMD patients.
Besides, it is important to realize that these findings are mutation specific as a smaller 
in-frame deletion in this same area, such as a deletion of exons 48-49, results in X-linked 
dilated cardiomyopathy.5 Also the in-frame deletions of exon 51-61 and 51-63 will most 
probably result in a moderate to severe phenotype, because they are close to the cysteine 
rich region (exon 64-70) which may affect the binding of dystrophin to β-dystroglycan.153 
Mice with such a deletion have muscles with severe dystrophic pathology.154 Furthermore, 
a deletion of exons 45-55 is associated with a BMD phenotype with a prognosis of a fa-
vorable outcome,155 but can also be associated with X-linked dilated cardiomyopathy de-
pending on the exact location of the breakpoints of the deletion.156, 157
Given the many different mutations, patients will benefit highly of multidisciplinary coop-
eration that results in databases with information on genotype as well as on phenotype.158 
For the dystrophinopathies good databases will facilitate and accelerate the inclusion of 
patients in clinical trials. This underlines the importance of setting up national patient 
registries, which can contribute to an international database. A good example of such a 
database is the TREAT NMD network of excellence (http://www.treat-nmd.eu/home.php).
In conclusion, the phenotype of BMD patients with a deletion of exons 45-51 and 50-51 
appears to be mild. This is encouraging for the outcome of the exon 51 skipping trials and 
offers hope to DMD patients who are eligible for this therapy.
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abstract
Objective 
Duchenne muscular dystrophy (DMD) is characterized by progressive muscle weak-
ness caused by DMD gene mutations leading to absence of the full-length dystro-
phin protein in muscle. Multiple dystrophin isoforms are expressed in brain, but little 
is known about their function. DMD is associated with specific learning and behavior-
al disabilities which are more prominent in patients with mutations in the distal part 
of the DMD gene, predicted to affect expression of shorter protein isoforms. We used 
quantitative MRI to study brain microstructure in DMD.
Methods 
T1-weighted and diffusion tensor images (DTI) were obtained on a 3 tesla MR scanner 
from 30 patients and 22 age-matched controls (ages 8-18 years). All subjects under-
went neuropsychological examination. Group comparisons on tissue volume and DTI 
parameters were made between DMD and controls, and between two DMD sub-
groups that were classified according to predicted Dp140 isoform expression (DMD_
Dp140+ and DMD_Dp140-).
Results 
DMD patients had smaller total brain volume, smaller grey matter volume, lower 
white matter fractional anisotropy, and higher white matter mean and radial diffusiv-
ity than healthy controls. DMD patients also performed worse on neuropsychological 
examination. Subgroup analyses showed that DMD_Dp140- contributed most to the 
grey matter volume differences and performed worse on information processing. 
Interpretation 
Grey and white matter is affected in DMD at a whole-brain level. Differences between 
subgroup DMD_Dp140- and controls indicate an important role for the Dp140 dystro-
phin isoform in cerebral development. 
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Introduction
The X-linked disease Duchenne muscular dystrophy (DMD) is characterized by severe and 
progressive muscle weakness due to mutations in the DMD gene. Mutations cause the 
absence of dystrophin, a 427 kDa protein.116 Dystrophin provides structural stability by 
connecting the contractile filament actin and the dystrophin-associated glycoprotein 
complex in the sarcolemma. In addition to muscle weakness, DMD is characterized by 
cognitive impairment which is thought to be non-progressive. In patients, the mean full-
scale intelligence quotient (FSIQ) is approximately one standard deviation below normal.42 
DMD patients exhibit problems with verbal short term memory, visuospatial long term 
memory and verbal fluency.159In addition, a higher incidence of autism spectrum disorders, 
attention deficit and hyperactivity disorders (ADHD) and obsessive-compulsive disorders 
occurs, as well as specific learning disorders such as dyslexia have been described.43, 45, 48
In the central nervous system (CNS), full length dystrophin (Dp427) is expressed mainly 
in cortical neurons and cerebellar Purkinje cells, but little is known about its function.160 
At least four shorter isoforms of dystrophin are also present in the CNS with molecular 
weights of 260, 140, 116 and 71 kDa respectively. These isoforms derive from alternative 
tissue specific promoter sites that use the following exons as the N–terminal domain, exon 
30 for Dp260, exon 45 for Dp140, exon 56 for Dp116 and exon 63 for Dp71.161 Cognitive 
impairment is more prominent in patients with mutations in the distal part of the DMD 
gene (downstream of exon 44) that are associated with the loss of Dp140 expression. This 
suggests a genotype-phenotype correlation between mutation and brain involvement.121
Post-mortem studies of DMD patients have not shown consistent abnormalities.162, 163. 
However, on a micro scale, architectural alterations in the cortical-spinal system and the 
parvalbumin and calbindin-positive cortical circuitry have been found in a mouse model 
for DMD. 164-166 Radiological studies in DMD patients showed glucose hypometabolism 
using positron emission tomography (PET) and altered metabolite concentrations with 
magnetic resonance spectroscopy.167-169 Magnetic resonance imaging (MRI) studies in 
DMD are limited to case reports and one quantitative study using voxel-based morphom-
etry analysis and resting state fMRI with a region of interest in the motor cortex.170 How-
ever, quantitative information on in vivo whole brain morphology and microstructure in 
DMD is not available. 
The aim of the present study was to investigate the brain in DMD using quantitative MRI to 
assess grey and white matter volume and microstructure. Composite scores for cognitive 
and behavioral functioning were analyzed in relation to MRI data. Finally, MRI data and 
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composite scores were compared between two DMD subgroups with different mutations 




DMD patients were recruited from the Dutch Dystrophinopathy Database, a nationwide 
patient registry. Exclusion criteria were the presence of MRI contraindications and the in-
ability to lie supine for at least 30 minutes. DMD diagnosis had previously been confirmed 
using DNA extracted from whole blood taken from patients by a Gentra Puregene DNA 
purification kit (Gentra Systems, Minneapolis, USA), following the manufacturer’s instruc-
tions. Deletion/duplication analysis of the DMD gene was performed using multiplex liga-
tion-dependant probe amplification (MPLA kit Salsa P034/P035 MCR-Holland, Amsterdam, 
The Netherlands). Small mutations were identified by means of high resolution melting 
curve analysis (HR-MCA) and subsequent sequence analysis.135 Within the recruited pa-
tients, two patient subgroups were distinguished (Figure 1). Patients carrying mutations 
upstream of intron 44 (transcription start site) were considered Dp140+. Patients with mu-
tations involving exon 51 (translation start site) or the genomic region downstream of 
exon 51 were considered Dp140-. Deletions with 3’ breakpoints in intron 44 were consid-
ered Dp140+ in case the breakpoint was upstream of the Dp140 promoter and unique first 
exon. A polymerase chain reaction (PCR) based approach assessed whether the Dp140 
promoter and first exon were deleted using the forward primer Dp140F 5’-ctttgtgcggagg-
cattg-3’, and the reverse primer Dp140R3 5’-CCAGCTTTTAGGCACACACA-3’. A second PCR 
was performed for these patients to confirm the presence of exon 51 using the forward 
primer hEx51F 5’-ggcttggacagaacttaccg-3’ and the reverse primer h51r 5’-cttctgcttgatgat-
catctc-3’. Patients carrying deletions in the region between intron 44 and exon 51 were ex-
cluded due to the unpredictable effect on Dp140 expression. All protocols were approved 
by the local Medical Ethical Committee. All participants or their legal representatives pro-
vided written informed consent. 
Procedures
The protocol was designed such that all tests could be performed on the same day. The 
Brooke scale for upper extremity function and Vignos scale for lower extremity function 
were used as a measure of muscle function.171 Participants were taken to a dummy scanner 
to familiarize themselves with the sounds and layout of an MRI machine. Subsequent neu-
ropsychological evaluation (NPE) lasted a maximum of one hour. MRI scanning was then 
performed on a 3T scanner (Philips Achieva, Philips Healthcare, Best, The Netherlands) us-
ing an 8 channel receive-only headcoil. Participants were placed supine with legs slightly 
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elevated for comfort. 3D T1-weighted (T1w; echo time (TE) and repetition time (TR) 4.6/9.8 
ms; spatial resolution 1.17x0.92x1.2 mm; 4:55 min), T2-weighted (T2w; TE/TR 80/4000 ms; 
spatial resolution 0.5x0.46x3.6 mm; 2:46 min), fluid attenuated inversion recovery (FLAIR; 
TE/TR 120/10000 ms; spatial resolution 1x0.8x3.6 mm; 4:00 min), and diffusion tensor (DTI; 
TE/TR 56/9440 ms; spatial resolution 1.96x2x2 mm; 32 directions, b=0 and 1000 s/mm2; 
6:40 min) images were obtained parallel to the corpus callosum. An independent neu-
roradiologist assessed the scans for gross structural abnormalities and incidental findings.
Neuropsychology
Three composite scores were constructed using predefined parts of standardized and 
validated instruments reflecting the most important aspects of neuropsychological and 
behavioral/emotional functioning in DMD 172. The first composite score represented read-
ing (scores standardized for age with a range of 1-19, mean 10 and standard deviation 3 in 
healthy controls) and was based on the mono-syllabic word reading test and the one min-
ute reading test derived from CB&WL: “continu benoemen en woorden lezen” (Bos & Lutje 
Spelberg, Boom test uitgevers, Amsterdam, The Netherlands). The second composite score 
represented information processing (scores standardized for age with a range or 1-19, mean 
10 and standard deviation 3 in healthy controls), and used two subtests from the Kaufman 
Figure 1. Dp140 transcription and translation sites used for subgroup classification
The prediction of Dp140 expression is based on mutation location in the DMD gene. There is a large gap between 
the start of transcription and start of translation for Dp140. Patients with a mutation starting and ending exactly 
in between transcription and translation were excluded from the analyses due to unpredictability of the mutation 
effect on Dp140 expression.
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Assessment battery (number recall for auditory working memory and block counting for 
conceptual thinking) and one subtest from the Wechsler Intelligence Scale for Children 
(symbol search). The third composite score for emotional and behavioral problems (range 
0-40) was constructed on the basis of the four problem based subscales from the Dutch 
version of the Strengths and Difficulties Questionnaire for parents. 173 The Personal Adjust-
ment and Role Skills scale (PARS) –III, a parent report measure studied in 287 DMD patients, 
was used to assess psychosocial adjustment.174 General intellectual level was assessed by 
the Peabody Picture Vocabulary test (PPVT-III-NL). This test measures receptive vocabu-
lary, is normalized for age, and requires no motor response. It was previously used in 130 
Duchenne boys.175
MrI
T1w and DTI scans were analyzed with FSL software v5.0.176 Intracranial volumes were ob-
tained using the Brain Extraction Tool with BET2 + betsurf (BET v2.1)177 with a fractional inten-
sity threshold (f) of 0.35. Grey matter, white matter and cerebrospinal fluid (CSF) were seg-
mented using the automated segmentation tool FAST.178 Quantification of the volumes was 
performed with fslstats -V using the partial volume corrected output from FAST. Diffusion 
tensor imaging scans were corrected for motion and distortion using ExploreDTI.179 Explore- 
DTI descriptive statistics was used to calculate mean whole brain FA and MD. Maps of axial 
diffusivity (AxD), radial diffusivity (RD), fractional anisotropy (FA) and mean diffusivity (MD) 
were also created. These maps were then exported for tract-based spatial statistics (TBSS) 
in FSL.180 
Statistical analysis
PARS and PPVT-III-NL scores of the DMD group were compared to known DMD popu-
lations using one sample t-tests. One sample t-tests were also used to test volumetric 
differences in whole brain intracranial, white matter, grey matter, and CSF volumes, as well 
as NPE scores between patients and controls. To correct for multiple comparisons, we 
used the method of Benjamini and Hochberg which limits the false discovery rate (FDR) to 
5%.181 One-way ANOVA was used to assess differences in these same parameters between 
the subgroups DMD_Dp140+, DMD_Dp140- and controls. 
A univariate general linear model with Duchenne status yes/no was used to assess the 
relation between three whole brain MR measures decided upon before the analysis to 
reduce multiple comparisons (grey matter volume, mean FA and mean MD) and the neu-
ropsychological composite scores for each group, and to assess the relation between the 
whole brain MR measures and age. All analyses were performed using SPSS v20.0 (IBM 
Corp., NY, USA) and considered significant at p<0.05.
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To localize MRI findings in specific areas of the brain, voxelwise statistical analyses were 
performed. For grey matter, voxel-based morphometry analysis (VBM) was performed 
with FSL-VBM.182 For white matter, FA, MD, RD and AxD, data were analyzed with age as 
covariate using Tract-Based Spatial Statistics (TBSS).180 An additional TBSS analysis was per-
formed with ICV and TBV as covariates to assess the relationship between volume and 
white matter microstucture. The aligned maps from each subject were projected onto 
the FA skeleton, and the resulting data used for voxel-wise cross-subject statistics using 
RANDOMISE ttest_2 with multiple comparison correction tcfe_corrp.183 
Figure 2.  representative t1w-images 
A 14 year old boy with DMD is depicted on the left and an age-matched healthy control on the right. Images are 
displayed in the radiological convention with the left hemisphere on the right of the image. Note the absence of 
gross structural differences between the patient and the age-matched healthy control, which explains why routine 






Thirty-three DMD boys (ages 8-18 years) and twenty-two healthy age-matched control 
boys (ages 8-16 years) participated in the study. Three DMD boys were excluded because 
they withdrew informed consent prior to the MRI scan (n=2), or the scans could not be 
made due to technical problems (n=1). In five DMD boys, one or more of the MRI scans 
could not be evaluated due to motion artifacts (one T1w and five DTI), leaving 29 DMD 
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due to motion artifacts. Some NPE tests could not be completed within one hour prior to 
the MRI, resulting in the missing composite scores. Clinical characteristics and an overview 
of the available MRI and NPE assessments are summarized in Table 1. Representative T1w 
images are shown in Figure 2. DMD general intellectual level was not different from data 
reported in the literature using the PPVT-III (97.56 vs 98.15 respectively).159 Psychosocial ad-
justment, reflected by the PARS-III score, was significantly better than in historical controls 
(91.62 vs 84.43, p<0.001).174 From the 29 DMD patients, 12 were classified as DMD_Dp140+ 
and 12 as DMD_Dp140-. Five DMD patients were excluded from the subgroup analysis be-
cause of the unpredictability of the mutation effect on Dp140 expression. No mutations 
downstream of exon 56 containing promoter sites of Dp116 and Dp71 were found. 
TABle 1. Patient characteristics and available assessments
Control dmd dmd _ dP140+ dmd _ dP140-
Participants (n) 22 29 12 12
Age (years)* 13.1 (2.0) 12.3 (2.8) 13.1 (3.3) 12.0 (2.7)
Range (years) 8-16 8-18 9-18 8-16
Steroid treatment (n) - 24 10 10
On/off 10 cycle (n) - 22 10 9
Brooke scale* 1 2.1 (1.6) 2.0 (1.6) 2.5 (1.7)
Vignos scale* 1 5.9 (3.1) 6.2 (3.1) 6.1 (3.2)
Wheelchair bound (n) - 15 7 6
Age of loss of am-
bulation (years)*
- 10.2 (2.1) 11.0 (2.6) 9.9 (1.3)
Regular education (n) 22 17 8 6
Reading compos-
ite score (n)
21 25 11 12
Information com-
posite score (n)
21 27 11 12
SDQ composite score (n) 22 28 11 12
3D T1 scans (n) 22 29 12 12
DTI scans (n) 21 25 10 10
* Data are presented as mean with standard deviation.  n: number of participants; SDQ: Strengths and Difficulties 
Questionnaire (for emotional and behavior problems); 3D: 3 dimensional; DTI: diffusion tensor imaging
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MrI
Visual assessment of the T1w, T2w and FLAIR images did not reveal any gross structural brain 
abnormalities. Quantitative analysis of the T1w images showed a significantly smaller total 
brain and grey matter volume in DMD patients compared to controls (Table 2). Intracranial 
volume was also smaller in DMD, although this difference failed to reach statistical signif-
icance (p=0.056). Adding intracranial volume as a covariate in the analysis of grey matter 
and total brain volume showed that these structures were not smaller compared to total 
intracranial volume. VBM analysis showed small regions within the occipital cortex and the 
left insula that were significantly smaller in patients compared to controls (Figure 3a). 
White matter FA was significantly lower in DMD in the occipital lobe (Figure 4). Significant-
ly higher MD in DMD was found mainly in the corpus callosum. RD was significantly higher 
in DMD throughout the white matter. Taking ICV and TBV as covariates in the TBSS analysis 
revealed a relationship between these parameters and all three DTI measures, while part 
of the occipital lobe showed changes in FA and RD independent of volumetric parameters 
(data not shown). 
DMD_Dp140- patients had the smallest grey matter, total brain and intracranial volumes 
(Figure 5a-c). VBM analysis showed differences between DMD_Dp140- and controls in a 
different but similarly small area as found in the whole DMD group versus control analysis 
(Figure 3b). TBSS showed similar results for DMD_Dp140+ and DMD_Dp140- versus control 
with significantly lower FA and higher RD, but no differences in MD. There was no effect of 
age on grey matter, white matter or total brain volumes. However, age did correlate with 
white matter microstructure, with higher FA and lower MD and RD with increasing age.
TABle 2.  Brain structure volumes in DMD patients and age-matched controls
Volumes Control dmd dmd _ dP140+ dmd _ dP140-
Intracranial (cc) 1651 ± 95 1584 ± 137 1633 ± 149 1550 ± 123
Total brain (cc) 1430 ± 78 1355 ± 118 * 1401 ± 121 1324 ± 114 *
Grey matter (cc) 811 ± 42 757 ± 56 *** 770 ± 53 749 ± 63 ***
White matter (cc) 619 ± 45 598 ± 70 631 ± 75 576 ± 61
CSF (cc) 222 ± 30 229 ± 32 232 ± 39 226 ± 29
Significant differences between patient groups and controls are indicated by * for p<0.05 and *** for p<0.001 after 
multiple comparison correction. CSF: cerebrospinal fluid
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Figure 3.  Grey matter voxel-based morphometry results
 
Local grey matter reductions in part of the left insula and occipital lobe are demonstrated by VBM when comparing 
the whole patient group to controls (a). Local grey matter reductions in part of the lingual gyrus and left cerebellar 
cortex are demonstrated by VBM when comparing the DMD_Dp140- subgroup to controls (b). No differences were 
found between DMD_Dp140+ and controls (data not shown). Images are displayed in the radiological convention 
with the left hemisphere on the right side.
a DMD vs Controls 
VBM
B DMD_Dp140- vs Controls
VBM
c-straathof-binnenwerk_zw_100gprint_3mmbleed-versie2.indd   70 15-9-2014   13:25:43
71
Reduced grey matter volume and altered white matter microstructure in Duchenne muscular dystrophy 
4
Figure 4.  DtI analyses of the white matter
Widespread alterations in white matter with reduced fractional anisotropy (FA) in the occipital lobe, and increased 
mean diffusivity (MD) and radial diffusivity (RD) throughout as demonstrated by tract-based spatial statistics (TBSS). 
DMD vs Controls 
Fa MD rD
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Figure 5.  t1w volumes and composite scores
 
Subgroup analyses for controls (black) DMD_Dp140+ (grey) and DMD_Dp140- (white). Volumes (cc) of the intracra-
nial (a), total brain (b) and grey matter (c) are depicted on the left. Composite scores for information processing (d), 
reading (e) and emotional/behavioral problems  derived from Strengths and Difficulties Questionnaire (SDQ)  (f) are 
shown on the right. Significant differences between groups are indicated by * for p<0.05, ** for p<0.01  after multiple 
comparison correction. 
B  Total brain volume
C  Grey matter volume






A  Intracranial volume
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Neuropsychological parameters 
All three NPE composite scores were significantly different between DMD patients and 
controls, with DMD patients performing worse. Subgroup analysis showed that DMD_
Dp140- patients performed worst on all composite scores, although this difference was 
statistically significant only for information processing. Scores of DMD_Dp140+ patients 
were between DMD_Dp140- and controls (Figure 5d-f). Within each subgroup, there were 
no significant correlations between the three composite scores and whole brain grey mat-
ter volume, whole brain FA or whole brain MD using the univariate general linear model.
Discussion
In DMD patients, grey matter and total brain volume are smaller, and white matter micro-
structural integrity is altered compared to healthy age-matched controls. Strikingly, com-
parison of DMD patients with and without Dp140 expression with controls shows that 
DMD_Dp140- patients, in whom the expression of the Dp140 isoform is predicted to be 
impaired, were more severely affected in terms of total brain and grey matter volumes as 
well as neuropsychological scores. 
The smaller grey matter volume in DMD is global, as the regions in the occipital lobe and 
left insula identified by VBM are too small to account for the difference. This is in contrast to 
a previous quantitative MRI study in DMD brain, in which VBM identified a smaller volume 
in the left primary sensorimotor cortex, although no analysis of absolute grey matter vol-
umes was performed.170 One CT study reported smaller grey matter volume in 20 out of 30 
DMD patients and contributed this difference to cortical atrophy. In the present study, skull 
size was proportional to total brain volume. There is a dynamic interaction between the 
developing brain and skull growth,184, 185 with 25-27% increase in whole brain and intracra-
nial volume between early childhood and adolescence. Therefore, correcting total brain 
volume with respect to intracranial volume enables the detection of atrophy. This implies 
that, smaller brains in DMD are due to differences in maturation rather than atrophy.
In contrast to grey matter, white matter showed no difference in volume, but was signifi-
cantly affected on a microstructural level as shown by DTI. The smaller FA and higher MD 
found in DMD indicate compromised structural complexity, and suggest reduced fiber 
density, increased membrane permeability, and/or decreased structural organization.186 
The higher RD in DMD indicates more fiber branching, decreased structural organization, 
or demyelination which can lead to increased membrane permeability.187, 188 The white 
matter microstructural differences between DMD and controls were associated with intra-
cranial and total brain volume, although these cross-sectional data do not allow any con-
c-straathof-binnenwerk_zw_100gprint_3mmbleed-versie2.indd   73 15-9-2014   13:25:43
74
Part 2 / Chapter 4
clusions regarding a causal relationship between the two. The global nature of the reduc-
tion in grey matter volume and microscopic nature of the white matter alterations could 
explain why these changes have not been described in previous post mortem studies and 
conventional MRI studies, as they can only be observed with whole brain quantitative MRI.
The global reduction in grey matter volume of patients could be related to the fact that 
full length Dp427, affected in all patients, is normally located in cortical and hippocampal 
pyramidal cells, the fetal cerebral cortex and cerebellar purkinje cells.160.160 In our DMD_
Dp140- subgroup, no mutations downstream of exon 56 were found. This implies that 
differences in MRI and NPE assessments in this study are mainly due to a lack of expression 
of the Dp140 isoform and do not include Dp116 and Dp71. The involvement of the Dp140 
isoform in cognitive impairment was previously identified.121 Dp140 is predominantly ac-
tive during fetal development in the astroglial processes.160 DMD patients with mutations 
disturbing Dp71 expression were even more severely affected mentally.189 Therefore, the 
loss of more dystrophin isoforms may well have a cumulative effect on altered brain mat-
uration. The correlation analyses did not reveal a significant association between mean 
whole brain grey matter volume, FA or MD and the neuropsychological composite scores 
within the groups. A modest, yet significant association between grey matter volume and 
total IQ was previously reported by Reiss et al185 in 69 healthy children. Our study was not 
powered to find such function to morphology associations within the group of DMD pa-
tients or controls, but aimed at finding differences between these groups. 
There are two potentially confounding issues in this study, which need to be specifically 
addressed. First, the brain still undergoes crucial developments in the age range of our 
subjects. Maximum global grey matter volume is reached between 6-9 years of age, after 
which it linearly declines approximately 5% per decade.184  White matter volume increases 
substantially from infancy through early adulthood with changes in myelination and axo-
nal packing.190 Age had a significant effect on FA, MD and RD which is in line with recent 
results.190 This made a correction for age essential in the TBSS analysis despite matching for 
this parameter upon recruitment. 
Secondly, the steroid treatment could have affected brain morphology. Volume reduc-
tions of hippocampus and amygdala have been observed in patients with asthma or 
rheumatic diseases receiving steroid treatment.191 Children with excess endogenous glu-
cocorticoids due to Cushing syndrome showed a significantly smaller total brain volume, 
larger ventricles, and smaller amygdala volumes than controls.192 Five DMD patients in our 
study were steroid naïve or had only been on steroid treatment for a short period of time 
at least ten years before participating. Two of these patients were in DMD_Dp140+ and 
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two in DMD_Dp140-. Given that DMD_Dp140- showed the most extensive differences 
with controls in all tests, this strongly suggests that steroid use cannot be the main con-
tributor to the morphological findings. However, a secondary contributing effect of the 
steroids on the morphological MRI findings cannot be excluded.
In conclusion, we observed significant global morphological and microstructural differ-
ences in the brain between DMD boys and controls. Results suggest that these differenc-
es arise from altered brain maturation rather than atrophy. Differences between DMD_
Dp140+ and DMD_Dp140- patients indicate an important role for the Dp140 dystrophin 
isoform in cerebral development. Future studies could include longitudinal data to con-
firm the lack of atrophy or focus on assessment of the structural and functional connectiv-
ity between different brain networks (the connectome) and hopefully further dissect the 
role of each of the dystrophin brain isoforms.
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abstract
Muscle hypertrophy and muscle weakness are well known in Duchenne Muscular 
dystrophy (DMD). Decreased muscle force can have secondary effects on skeletal 
growth and development such as facial and dental morphology changes. In this 
study we quantified temporal muscle thickness, circumference and eccentricity of 
the skull and the head on T1-weighted MRI scans of the head of 15 Duchenne mus-
cular dystrophy patients and 15 controls. Average temporal muscle thickness was 
significantly increased in patients (12.9 ± 5.2 mm) compared to controls (6.8 ± 1.4 
mm) (p<0.0001), whereas the shape of the skull was significantly rounder compared 
to controls. Temporal muscle thickness and skull eccentricity were significantly neg-
atively correlated in patients, and positively in controls. Hypertrophy of the tempo-
ral muscles and changes in skull eccentricity appear to occur early in the course of 
Duchenne muscular dystrophy. Further studies in younger patients are needed to 
confirm a causal relationship. 
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Introduction
Duchenne muscular dystrophy (DMD) is characterized by progressive weakness of skele-
tal, respiratory and cardiac muscles due to the absence of dystrophin. Medical and sup-
portive care have improved life expectancy from 20 up to 25-30 years. Muscle weakness in 
the legs usually manifests itself when a boy begins to walk on his toes and falls frequently. 
A prominent feature is calf hypertrophy, which in combination with a disturbed walking 
pattern and increased serum creatine kinase level suggests the clinical diagnosis of DMD.
Muscle hypertrophy in DMD is not restricted to the calf muscles, but has also been re-
ported in other muscle groups. Specifically, the gracilis and sartorius muscles in the upper 
legs, deltoid and infraspinatus muscles in the shoulder region and the tongue can be 
hypertrophic193,194 One case report has described temporal muscle hypertrophy in DMD.195 
It is likely that muscle hypertrophy in DMD is a response to dysfunction of weak skeletal 
muscles. It is currently not known if hypertrophy in DMD leads to an increase in muscle 
strength.196,197 Mechanical forces exerted by skeletal muscles can influence bone struc-
ture198 and, therefore, secondary effects of muscle weakness or hypertrophy could lead 
to differences in bone development. For example, decreased bite force has been sug-
gested as related to skeletal changes in the oral-facial region.199,200 Furthermore, dental 
malocclusion in DMD has been described as a result of imbalance of muscle strength in 
the orofacial region and developmental changes in jaw bones.200 During an MRI study of 
the brain in DMD patients we consistently observed temporal muscle hypertrophy and a 
different skull shape compared to healthy age-matched controls. The difference was so 
pronounced that, given the knowledge of the impact that skeletal muscle force can have 
on bone, we choose to quantify and report our observations.
Methods
Subjects
15 Caucasian DMD boys (8-16 years) and 15 age-matched healthy Caucasian (9-15 years) 
boys participated in the study. Patients were recruited from the Dutch dystrophinopa-
thy database. Only patients with a genetically confirmed diagnosis were included. Con-
trols were recruited from schools or sports clubs. In patients using steroids (intermittent 
scheme, 10 days on, 10 days off) the scans were performed during the off-period. The 
study was approved by the institutional Ethics Committee. All participants and their par-
ents gave informed consent.
c-straathof-binnenwerk_zw_100gprint_3mmbleed-versie2.indd   79 15-9-2014   13:25:44
80
Part 2 / Chapter 5
Mr imaging
Three-dimensional T1-weighted images (echotime (TE) 4.6ms, repetition time (TR) 9.8ms, 
voxel size 1.17 x 1.17 x 1.2 mm, acquisition time 4:56min) of the head were obtained at 3T 
(Achieva, Philips Healthcare, Best, The Netherlands) using an 8-channel head coil. Quan-
titative determination of eccentricity and circumference of the skull (excluding muscles, 
fat and skin) and the head (including muscles, fat and skin) was performed by two inde-
pendent observers. Transversal images from each boy were assessed from the anterior 
and posterior commissure (AC/PC) upwards (reconstructed to 10 slices, 1.5 mm thick, 2.0 
mm slice gap). Regions of interest (ROIs) of skull and head were manually drawn in MIPAV 
(http://mipav.cit.nih.gov) and averaged for the 10 slices. MIPAV was also used to determine 
the largest cross-section of left and right temporal muscles.
Statistics
Differences in skull eccentricity, head eccentricity, temporal muscle thickness, skull cir-
cumference and head circumference between DMD and controls were assessed. This was 
done using the values averaged for two independent observers by means of a Students 
t test with Welch’s correction were the variances where significantly different. Interob-
server variability was computed using the Intraclass Correlation Coefficient (ICC). Pearson 
correlation was computed between skull eccentricity and temporal muscle thickness, age 
and temporal muscle thickness, and between age and eccentricity. Statistical significance 
was set at p<0.05. Statistical analyses were performed by using SPSS (version 17.0, SPSS Inc, 
Chicago, IL, USA)
results
Descriptive data of the participants are shown in Table 1. On visual inspection of the im-
ages, hypertrophy of the temporal muscles was observed in all DMD patients as well as a 
rounder shape of the head compared to more ovoid shaped in healthy controls (Figure 1). 
The average cross-sectional temporal muscle size was 12.9 ± 5.2 mm in DMD compared to 
only 6.8 ± 1.4 mm in controls (p<0.001; Figure 2A). In controls, a positive correlation between 
temporal muscle size and age was observed, while in DMD no such relation was observed 
(Figure 2B). The ICC for measurements of eccentricity and circumference of the skull and 
head was 0.994 ± 0.001. The circumference of skull and head showed no significant differ-
ence between DMD and controls. As a parameter for shape, eccentricity was calculated from 
ROIs drawn on head circumference and on skull circumference (Figure 1). Eccentricity ranges 
between 0 and 1, in which “0” represents a perfect circle and “1” a parabola. 
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TABle 1   Descriptive data of the participants
dmd n=15 Controls n=15
age
Mean ± SD 12.4 ± 2.7 12.4 ± 1.7
Median (range)  14.0 (8-16)  12.9 (9-15)
Use of Steriods (n)
Current use 12 0
Stopped >1year 2
Never used 1
Wheelchair bound (n) 9 0
Head circumference (cm)
Mean ± SD 56.0 ± 2.8 55.5 ±1.4
Range 52.5-60.0 53.0-58.5
Figure 1 t1-w MrI scans of the head
Transverse sections taken parallel to the anterior and posterior commissure (AC/PC) of a healthy 10-year-old boy 
(left) and 10-year-old boy with DMD. The DMD boy shows a rounder head and skull shape and bilateral temporal 
muscle hypertrophy (indicated by arrows). 
Controls DMD
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Figure 2.  temporal muscle thickness and skull morphology in DMD boys and 
   healthy age matched controls
In all images DMD is depicted in black and control in grey.
A:   average thickness of left and right temporal muscles with SEM in DMD and in controls.
B:   correlation between temporal muscle thickness (averaged values for left and right) and age in DMD and in 
  controls. Indicated by # is a DMD boy that has never used steroids.
C:    eccentricity (0=perfect circle, 1= parabola) of the head and the skull with SEM in DMD and in controls. 
D:    correlation between temporal muscle thickness and skull eccentricity in DMD and controls; in DMD larger 
  temporal muscle size correlates to a rounder skull shape, but in controls larger temporal muscles correlate to 
  a more ovoid shaped skull.
* =   p<0.05
*** =  p<0.0001
SEM:  standard error of the mean
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The average skull eccentricity in DMD (0.59 ± 0.05) was significantly different from skull ec-
centricity in controls (0.63 ± 0.05) (p<0.05; figure 2C). DMD boys had a rounder skull shape 
and controls had a more ovoid shaped skull on transversal images. Skull eccentricity was 
not correlated with age. 
Finally, a significant correlation between temporal muscle size and skull eccentricity was 
observed (figure 2D). In DMD, thicker (hypertrophic) temporal muscles were related to a 
rounder shaped skull (r=-0.54; p=0.04). In controls, thicker temporal muscles were correlat-
ed with an ovoid skull shape (r=0.55; p=0.03). 
 
Discussion
Our results showed systematic temporal muscle hypertrophy in DMD boys which is clearly 
apparent on transverse MR images of the head. Additionally, in the transverse plane, the 
shape of the skull in DMD patients is rounder compared to healthy age-matched controls. 
Temporal muscle hypertrophy and skull eccentricity are significantly correlated in DMD 
boys, whereby a thicker muscle is associated with a rounder skull. On clinical examina-
tion temporal hypertrophy is visible and palpable and should not be confused with a 
steroid-induced “moon face”. 
Hypertrophy of skeletal muscles is commonly observed after training and is associated 
with an increase in muscle strength. In DMD, however, hypertrophy of the leg muscles is 
not accompanied by an increase in strength but rather by a decrease in strength, indicat-
ing a lower quality of the increased muscle mass.196,197 It is unclear if the increased muscle 
mass of the temporalis muscles we observed results in an increased or decreased force, as 
we did not assess muscle strength of the temporalis muscles. Previous literature suggests 
that muscle force of the temporalis muscles decreases despite the hypertrophy, as bite 
force is known to be impaired in DMD patients above the age of eight.199,201 
In addition, our results show that thicker temporal muscles are associated with a more 
ovoid skull shape in controls. Taken together, this could suggest that the weaker, hyper-
trophic cranial muscles, among which the temporal muscles, influences the development 
of the skull, resulting in a rounder shape. We did not observe a correlation of skull shape 
with age. Therefore, it is likely that the changes in skull shape are present at a young age. 
In support of this suggestion are data from 7-week-old dystrophic (dy/dyC57BL/6J) mice 
where the anatomical shape of the skull and mandible was different compared to con-
trol mice. This would suggest that bone development is affected early in the muscular 
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dystrophy.202,203 Furthermore, histopathological dystrophic features were already present 
in the temporal muscles in 7-week-old mdx mice.204 An alternative hypothesis is that the 
observed skull shape is independent from temporal muscle hypertrophy, but generally 
related to bone differences such as short stature 205 and different bone mineral density206 
as recently described in DMD. 
As the majority of the DMD boys included in this study used chronic steroid treatment 
this could have influenced the changes we observed. Though hypertrophic muscles due 
to anabolic steroids have been reported 207, current literature does not describe any rela-
tion between corticosteroid use and muscle hypertrophy. On the contrary, corticosteroid 
therapy is known to result in muscle wasting and type II muscle fibre atrophy208, 209 In ad-
dition, Guillaume Duchenne described muscle hypertrophy in the 19th century210 when 
corticosteroid therapy was not yet present. As corticosteroid therapy is usually not initi-
ated in DMD before the age of 6 years, it is highly unlikely that steroid therapy is solely 
responsible for such a profound effect on skull morphology. Further studies in younger 
patients, preferably before they commence steroid treatment, could possibly clarify the 
pathophysiological mechanism of skull eccentricity and the relation to hypertrophy of the 
temporal muscles. 
Improvement of muscle strength and function is the main goal for new treatment strate-
gies in DMD. Future introduction of new therapies aimed at improving muscle strength, 
will it is hoped improve long-term outcome and life expectancy in DMD. Irreversible skel-
etal changes may limit recovery of muscle function. Therefore, it is important to pay atten-
tion to both the evaluation of muscle function as to skeletal deformation, such as we have 
described for the skull in this report.
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abstract 
Corticosteroids are effective in improving motor function in patients with Duchenne 
muscular dystrophy within 6 month-2 years of treatment initiation, but there is as yet 
no consensus on which treatment scheme is the best. We retrospectively analyzed 
data of 35 DMD patients who were treated with prednisone 0.75 mg/kg/day inter-
mittently 10 days on/10 days off. Prednisone was started during ambulant phase at 
age 3.5-9.7 years (median 6.5 years). The median period of treatment was 27 months 
(range 3-123 months). The median age at which ambulation was lost was 10.8 years 
(mean 10.9 years; 95% confidence interval 10.0-11.8 years). Nine patients (26%) had 
excessive weight gain. Eight boys (21%) had a bone fracture, which was when four 
of these eight children lost ability to walk. Treatment was stopped in two obese 
patients, in two hyperactive boys and in one patient following a fracture. Our data 
suggest that prednisone 10 on/10 off has relatively few side effects and extends the 
ambulant phase by 1 year compared to historical controls.
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Introduction
In 2004, Manzur et al. reported that corticosteroid treatment in Duchenne Muscular Dys-
trophy (DMD) effectively improves muscle strength for 6 months-2 years and improves 
respiratory muscle strength for 6 months.211 In 2005, published guidelines in the Nether-
lands advocated treatment of DMD patients with 0.75 mg/kg prednisone daily for at least 
the ambulant years.212 This conclusion was based on trials using daily dose corticosteroids, 
which proved to be superior to placebo213, 214 and to an alternate-day scheme (one day on/
one day off).215 Different doses as well as different intermittent schemes of administration 
have been tried in clinical trials with the aim of reducing major side effects.216-220 However, 
there is as yet no internationally accepted consensus on which corticosteroid treatment 
scheme is the best for patients with DMD. In addition, there has yet to be a randomized 
study involving a head-to-head comparison.
Until 2005 clinical experience with corticosteroids treatment in DMD patients had been 
scarce in the Netherlands and mainly restricted to a few rehabilitation physicians who pre-
scribed prednisone. In rehabilitation center De Trappenberg, however, young boys with 
DMD have been offered prednisone since 1996. The treatment was given in an alternating 
scheme, 10 on/10 off, in which 10 days prednisone 0.75 mg/kg/day was alternated with 10 
days without corticosteroids; this was in accordance with the dosage scheme of the Ham-
mersmith Hospital in London.221, 222 This particular therapeutic drug regimen was chosen 
on the assumption that a sustained clinical effect can be achieved during ten days corti-
costeroids, while side effects are decreased due to an off phase in which the pituitary-ad-
renal axis can restore its function.
Here, we describe a follow up study of these young DMD patients who were adminis-
tered this alternating prednisone therapy, with focus on motor skills and the side effects 
of prednisone.
Patients and Methods
Patients and clinical data
Between 1996 and 2005, 43 patients with DMD, accompanied by their parents, consulted 
the rehabilitation centre De Trappenberg for treatment with corticosteroids. We have stud-
ied the files of these patients retrospectively and evaluated the data. All patients showed 
progressive muscle weakness typical of DMD, and diagnosis was confirmed by DNA analysis. 
The rehabilitation physician (IG) and the pediatrician (GJB) performed the clinical monitoring. 
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The prednisone starting dosage was 0.75 mg/kg/day in an alternating schema of 10 days 
on and 10 days off. The treating physician adjusted the dose during growth. In the post-am-
bulant phase dose was lowered to 0.3-0.5 mg/kg/day 10 days on/ 10 days off. The following 
assessments were performed prior to the initiation of prednisone treatment and every six 
months thereafter: (1) time to run or walk 10 meters as fast possible; (2) time to stand up from 
a sitting position on the floor with crossed legs, with assistance of the hands, but no support 
from the wall or furniture. The time tests were performed independently of the phase of 
prednisone therapy. During the visits body weight, height and blood pressure were mea-
sured. Weight gain was interpreted with the Standard Deviation Score (SDS) on a weight-to- 
height growth chart. On this chart +2.0 SDS refers to the P98 percentile on the reference chart 
for Dutch children, whereas 0 SDS refers to the P50 percentile. Blood pressure was correlated 
to height and age and interpreted with a reference table.223
Radiological examinations of the spine in anteroposterior and lateral direction were per-
formed yearly in order to follow any development of scoliosis and to register subclinical 
vertebral fractures. The morning serum cortisone level was measured twice yearly during 
the off period. In the period 1996-2001 cortisone was measured on days 11, 16 and 20 at 
9 am and 4 pm. From 2002 onwards, only the morning cortisone level was measured on 
day 20, which is the last day of the off period. All patients received a standard advice to 
increase prednisone dose during periods of stress, like high fever or before surgery. The 
incidence of bone fractures and the age at which ambulation was lost were registered. 
Loss of ambulation was defined as being unable to walk unsupported indoors. 
Statistical analysis
Descriptive statistics are shown as median or mean ± standard deviation (SD).
The Kaplan Meier survival curve of ambulation was calculated with the help of SPSS ver. 
12.0 (SPSS, Chicago, IL).
results
Clinical data
The median age at which DMD was diagnosed was 4 years (range 9 months-10.4 years) 
while the median age at time of evaluation was 10.5 years (range 5- 18 years)
Eighteen patients (42 %) were living in the region of the rehabilitation center and the other 
25 patients were seen on tertiary referral base. Twenty-five boys (58%) were attending a 
regular school, and 18 were attending a special school for children with impaired motor 
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and/or cognitive skills. The parents of four patients decided, after receiving details of the 
treatment, not to start treatment with prednisone because of behavioral problems (three 
patients: autism/retardation) or a mild clinical pattern (one patient). Two of the untreated 
patients became wheelchair bound (WCB) following a leg fracture due to a trauma at age 
11.0 years and 12.6 years, respectively. The remaining 39 patients received prednisone for 
a period of 3-123 months (median 27 months, average 38 months). In four patients predni-
sone was started during the non-ambulant phase (Figure 1).
The median age at which prednisone was started was 6.5 years (range 3.5-9.7 years). The 
dosage of 0.75 mg/kg was adjusted to body weight during follow up, except in four boys 
because of obesity. After the loss of ambulation, the dosage of prednisone was lowered 
to 0.3-0.5 mg/kg.  
Scoliosis surgery was performed on two patients aged 13.5 years and 8 years, respectively. 
The former had used prednisone for 9 months until he became WCB at age 9.9 years. The 
second had already lost ambulation at the time of the operation- at age 6.5 years due to 
a femur fracture. No patient needed respiratory support during follow up. Three patients 
received cardiac medication from their cardiologist. 
Figure 1 Schematic overview of the cohort of patients with Duchenne muscular 
   dystrophy that were followed in De trappenberg between 1996-2005
WCB: wheelchair bound 
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Figure 2  Cumulative prolongation of ambulation plotted against age
Figure 3  results of the motor-time tests during the follow-up of the DMD 
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The median age at which ambulation was lost in the 35 prednisone treated patients was 
10.8 years (130 months; with a mean age of 10.9 years, 95% confidence interval (CI) 10.0-11.8 
years; Figure 2).
Functional scores 
The data obtained in the motor-time tests for 28 treated patients was evaluated (Figure 
1). The follow-up was less than 6 months in four patients and in two other patients the 
treatment was stopped due to hyperactivity. During the first months of treatment the 
time needed to perform the running or standing up test decreased or remained stable, 
subsequently increasing when disease progressed (Figure 3). 
 
Side effects
Side effects and complications of prednisone are shown in Table 1. Five patients stopped 
treatment due to side effects of whom three had lost ambulation at that time. Eighteen 
patients (46%) showed a weight gain on the weight-to-height growth chart during pred-
nisone (nine patients ≤ 1SDS weight gain, nine patients > 1 SDS weight gain). None of the 
ambulant boys had a weight gain of more than 1.0 SDS. The body weight in seven DMD 
patients was already at 1.0 SDS before the start of prednisone. 
Eight boys (21%) had a fracture during prednisone treatment, with trauma (falling) being 
the cause of the fracture in six boys; the cause was unknown in the other two boys. All four 
patients with a femur fracture became WCB due to the fracture. Two boys had a fore arm 
fracture and two others a lower leg fracture. Of the latter, one boy was only temporarily 
immobilized while the other had lost ambulation 6 months prior to the fracture. 
On one occasion, three boys had a systolic blood pressure (SBP) or diastolic blood pressure 
(DBP) level that was >95% percentile after correction for age and height. In two of them 
(one boy at age 10 following 5 years prednisone and the other at age 13 following 7.5 
years prednisone respectively) the cardiologist also found a diminished ejection fraction 
on echocardiography; treatment with an angiotensin converting enzyme inhibitor was 
commenced. In the third boy, high blood pressure was found three years after he had 
stopped prednisone; he was given digoxin but data on cardiac function were lacking. The 
blood pressure in all other patients remained < 95% percentile during follow up.
In the first group of 16 patients that received prednisone in the period 1996-2001, serum 
cortisone levels were very low to nearly zero on the first day without prednisone (day 11), 
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while in all patients the morning level restored to normal before restart of prednisone. 
From 2002 onwards, morning cortisone levels on day 20 were normal, except in two pa-
tients who had a low level of 0.08 µmol/l (reference 0.18-0.72 µmol/l) on one occasion. 
None of the patients suffered from adrenal insufficiency during the follow-up period. 
TABle 1:  reported side effects and complications in the cohort of 35 DMD 
   patients treated with prednisone 10 days on/10 days off.
side effeCts/ ComPliCations yes no reason to stoP steroids
Weight gain (n=32)  14
≤1 SDS 9
> 1 SDS 9  2
Body Height (n=28)
Average (0 SDS) 14
≤- 1 SDS 14   
Behavior problems (n=20) 4 hyperactive 12 2
 4 nycturia  0
Adrenal insufficiency day 20 (n=35) 0 35
Fracture (n=35) 8 27 1
Discussion
Among our pediatric patient group with DMD, the mean age at which patients treated with 
the 10 on/10 off prednisone scheme became WCB was 10.9 years. Comparable studies in 
which daily doses of steroids were used have reported a mean age of 11.5224 and 12.5 years225 
and those in which alternate-day high dose prednisone (1.3-2.0 mg/kg) were used have 
reported 14 226 or 12.2 years.227 However, a drop-out percentage of 55% was reported during 
daily prednisone 0.75 mg/kg/day due to obesity or infection-related complications.226
Control patients who were not treated in these non-randomized studies and DMD patients 
reported in historical series from 1967-2002 became WCB at mean age of 8.5-12 years.228-230 
The age at which ambulation is lost is a clinical meaningful endpoint to evaluate efficacy 
of treatment in DMD patients although it has not been a primary endpoint in randomized 
studies with steroids in DMD patients up until now.231 There is no clear consensus on the 
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definition of loss of ambulation. We used a rather practical definition that ambulation was 
lost if the patient could no longer walk in a household setting.232 Although the median 
treatment period was nearly two years, the patients in our series had a long-term follow 
up which allowed the construction of a Kaplan-Meier survival curve of the prolongation 
of walking. In four patients of our series, the follow up of ambulation during steroids was 
complicated by a leg fracture that resulted in the loss of ambulation. Our study reflects the 
daily practice of treatment with steroids in DMD. It provides important information when 
long-term benefits and side effects of steroid treatment are being evaluated.
In a study in which the inclusion criterion was a minimum of 4 years of treatment with de-
flazacort in an alternating 20/10 scheme, Biggar et al. 218 reported  that 35% of the patients 
were still ambulant at age 12. In young healthy children, functional scores like running or 
rising from the floor, improve as the child ages from 4 to 10 years due to the growth-related 
physiological increase in strength.143 In contrast, DMD patients in the same age group not 
treated with prednisone showed decreasing mean functional scores during childhood, 
due to progressive muscle weakness.143 Although we lack a control group, our patients 
showed an improvement or stabilization on their functional scores for at least 12 months 
while on the  prednisone 10/10 on/off therapeutic regimen (Figure 3). Most randomized 
studies have evaluated corticosteroid treatment using functional scores, with a surpris-
ingly large variation in outcome depending whether a metric or non-metric measure was 
chosen; for example time to run has been evaluated in 10 meters,217, 218  9 meters (30 feet)171, 
214, 215, 219, 220, 224 or 8.54 m (28 feet).221, 233
Time to stand up from the floor has also been  evaluated starting from a lying position,219, 
220 from sitting position with outstretched legs,217 sitting position with crossed legs, or not 
well defined. This diversity in evaluation endpoints makes it more difficult to compare 
studies using different schemes or dosages of corticosteroids. 
The main advantage of treatment with steroids in an alternating scheme instead of daily 
dose would be a similar efficacy with fewer side effects. In most studies evaluating ste-
roids in DMD, weight gain is an important problem. Studies in which the drug regimen 
consisted of daily dose 0.75 mg/kg/day have reported weight gain > 10% in about 75% of 
the patients,213, 214 while we found this in only 25% of our patients and, more remarkably, 
only in boys after they got WCB. Since seven of the eleven patients that reached a body 
weight of +2SDS had a body weight of +1SD before start of prednisone, the latter seems to 
be a risk factor for excessive weight gain. In our group, we found that 40% of the patients 
did not experience a weight gain, which is comparable to what others found in a small 
series of six ambulant DMD patients less than five years.222  
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The prevalence of bone fractures in our patients is in accordance with results of a previous 
study that found 21% fractures in treated as well as not treated DMD boys.234 Daily steroid 
treatment has been reported to increase the risk of long bone fractures by 2.6 fold.225 The 
majority of the patients was WCB, which is a risk factor for long bone fractures in untreated 
neuromuscular patients.234 Remarkably we did not find any vertebral fractures in intermit-
tently treated patients, which is in contrast to the reported 32% compression fractures 
in the daily steroid treated group.225 In our DMD cohort hypertension was not a primary 
problem of intermittent prednisone therapy, although in two patients did have a blood 
pressure >95% percentile concomitant with insidious cardiomyopathy.
In conclusion, our data show the results of long-term follow up in a large cohort of pa-
tients; these data  reflect the outcomes observed in daily practice. The retrospective na-
ture of the analysis and the lack of control group limit the interpretation of our results on 
functional scores. However, controlled studies on the effect of steroids often lack data on 
long-term endpoints, such as the development of scoliosis and cardiomyopathy. 
Until better evidence is available on long-term effects, the reporting of observational data 
can be helpful in terms of making future decisions on the continuation of steroids for DMD 
patients who have lost ambulation.
Compared to the daily prednisone therapeutic regimens used in other studies, the 10 
on /10 off does seem to be effective in extending ambulant phase in DMD boys; it is also 
well tolerated. Weight gain is an issue of concern, especially when ambulation is lost, but 
it seems to occur less often on the 10 on/10 off steroid regimen than when prednisone is 
administered daily. A prospectively randomized study, with internationally standardized 
endpoints would still be very useful in providing data for determining the best dose and 
the best scheme for steroid administration in DMD patients.
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Summary 
Duchenne muscular dystrophy(DMD) and Becker muscular dystrophy (BMD) are like mir-
ror images: alike but different. The two disorders share clinical features such as calf hyper-
trophy, proximal weakness, hyperCKemia and cardiomyopathy, but they are different con-
cerning clinical course, prognosis and therapeutic perspective. Both disorders are X-linked 
and allelic on the DMD gene, but whereas the protein dystrophin is virtually absent in 
muscle tissue of DMD patients, in BMD a partly functional dystrophin of different size can 
be produced. The lack of dystrophin in muscles of DMD patients results in progressive 
weakness which generally starts in childhood. If dystrophin is not lacking but expressed 
in reduced amounts or in an aberrant size, the clinical presentation of muscle symptoms 
is more variable, not only in severity but also in age of onset.131 Indeed clinical symptoms 
in BMD are highly variable ranging from mild symptoms, or even asymptomatic with only 
hyperCKemia, to severe muscle weakness in a limb girdle pattern. This heterogeneity may 
be the reason why diagnosis in BMD is often delayed.15
Diagnosis can be challenging in dystrophinopathies. In general, diagnosis in muscular 
dystrophies is the resultant of a good interpretation of clinical symptoms and signs in 
combination with the results of appropriate ancillary investigations ultimately leading to a 
molecular-genetic classification. 
In chapter 1 the different clinical phenotypes of dystrophinopathies are described and 
diagnostic steps are discussed. A rule of the thumb is that dystrophinopathy goes hand in 
hand with an elevated serum CK level. On the other hand the list of differential diagnoses 
in patients with hyperCKemia is long. Therefore diagnostic algorithms for asymptomatic 
and paucisymptomatic hyperCKemia are also discussed extensively in the first chapter 
and a schematic overview is given of neuromuscular disorders that may present with hy-
perCKemia. Nevertheless, molecular- genetic diagnosis is the mainstay in the diagnostic 
work up of dystrophinopathies. Information on the DNA mutation is important for several 
reasons: first to improve classification for individual patients, secondly for genetic counsel-
ing of family members and finally to guide future therapies in DMD. 
Part 1 of this thesis concerns BMD and two studies are presented. 
The study in chapter 2 deals with delayed diagnosis in BMD. We recently re-evaluated a 
cohort of 185 patients for whom DNA analysis was requested between 1985-1995. The 
DMD gene was the first gene for which DNA analysis became available for routine diag-
nostic testing in patients suspected to have a muscular dystrophy; the standard analysis 
method in the early period of DNA testing was screening for deletions and duplications in 
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the DMD gene. These large rearrangements account for 70% of the mutations in dystro-
phinopathies. More recently, newer techniques have been developed to screen for small 
mutations in the gene and currently DNA analysis of the DMD gene is a multiple step 
procedure. If no deletions or duplications have been found using conventional techniques 
like MLPA, sequencing of the DMD gene can be performed to detect small mutations. 
It was not known whether mutations had been missed and BMD was underdiagnosed in 
those patients that were referred for DNA analysis in the early period when sequencing 
to screen for small mutations was not yet available. In this study we were interested if ex-
tending the standard analysis by sequencing the DMD gene would improve the yield of 
diagnosis in patients in whom DNA analysis was requested in the early decade following 
cloning of the DMD gene. All requisition forms  of undiagnosed patients with suspected 
BMD were re-evaluated; if the available clinical information was compatible with BMD, 
stored DNA was re-analyzed and screened for small mutations. In this cohort re-analysis 
of DNA could be performed in 31 of 79 patients without a diagnosis. Eight different muta-
tions were found, including four novel mutations. Long term clinical follow up 15-25 years 
after initial referral was possible in all four patients with a novel mutation. The mutation 
is pathogenic and leading to a frame shift in at least three of them, including two pa-
tients with progressive limb girdle weakness and one patient with a somatic mosaic who 
was asymptomatic. In addition, in one patient a novel missense mutation was found and 
he had mild symptoms and hyperCKemia. The clinical relevance of a delayed, genetically 
confirmed, diagnosis of BMD is that screening for cardiomyopathy can be advised and 
that family members can be counseled and tested for carrier status. Late diagnosis was 
achieved because new techniques were applied. The clinical information provided by the 
referring physician at initial request for DNA analysis was helpful to clarify the diagnosis 
years later. In contrast, 22 of the undiagnosed 79 cases of the aforementioned cohort were 
excluded because the requisition forms did not include clinical data. We concluded that 
collaboration between clinician, molecular geneticist and clinical geneticist can improve 
the outcome in unsolved cases. One step in this collaboration is that clinical information 
and, if possible, data of follow up are shared with the geneticist. 
The clinical phenotype BMD is very interesting not only because its heterogeneity, but 
also because the phenotype may serve as a model for treatment of DMD. Currently treat-
ment strategies for Duchenne dystrophy are being developed with the potential to en-
able production of dystrophin in DMD patients. If the genetic defect in the muscle tissue 
is changed from out-of-frame to in-frame, resulting in restoration of the reading frame, 
dystrophin can be produced in the muscle fibers.105 Since a large spectrum of mutations 
in the DMD gene can cause DMD, customized treatment is required to restore the reading 
frame. Thus, depending on the location of the mutation, different  specific agents will 
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have to be developed. Exon skipping of exon 51 was the first treatment for DMD that was 
put on clinical trial.235 Skipping specific exons in DMD patients to enable dystrophin pro-
duction will result in an expected end product that is similar to the partly functional dys-
trophin in patients with BMD who have a deletion including the skipped exon. Chapter 3 
describes the phenotypes and clinical follow up of the two families with BMD in the Neth-
erlands that were known to have such a mutation. In all three patients the course of the 
disease was very mild. In the first family the index patient had come to medical attention 
at age 14 years because he was suffering from painful muscle cramps since childhood. His 
CK level was increased 50 times above normal and an in-frame deletion of exons 45-51 
of the DMD gene was found. His maternal grandfather, who also suffered from cramps 
in childhood and adolescence, carried the same mutation. Both males were examined at 
adult age and none of them had muscle weakness. The grandfather was asymptomatic at 
age 78 with a normal CK and the grandson had calf hypertrophy at age 46 with minimal 
exertional related muscle symptoms  and a marginally increased serum CK level. In the 
second family the index patient was eight years old when he was referred to a pedia-
trician for hyperactive behavior. High serum CK levels were found at routine laboratory 
investigation. DNA analysis of the DMD gene showed in-frame deletions of exons 50-51. 
He was re-examined at age 14 and had no muscle weakness. Sporadically he experienced 
exertional muscle cramps. He received medical treatment for his hyperactivity. The very 
mild clinical course in both BMD families could be promising for DMD patients who are 
eligible for exon 51 skipping.
Part 2 of this thesis concerns Duchenne muscular dystrophy. 
It is generally accepted  that the central nervous system is involved in DMD but the patho-
physiologic mechanism has not been elucidated yet.  Dystrophin, which has an important 
function in muscles, is also expressed in other tissues, including the brain. Besides the 
full-length dystrophin protein Dp427 several shorter isoforms are transcribed, which arise 
from  promotors  located more distally on the DMD gene. They are known as Dp 260, 
Dp140, Dp116 and Dp71, each with a preferential distribution in different tissues. (see also 
figure 3 on page 31).  More specifically, Dp140 and Dp71 are present in fetal brain and 
it is suggested that these isoforms are important for cognitive function.120 However, the 
precise role of dystrophin and its isoforms in the brain is not known. DMD patients with 
severe cognitive impairment often have a mutation in the distal part of the DMD gene.136, 
236 A relation between cognitive impairment and mutations that result in absence of iso-
forms Dp140 and Dp71 has been suggested.120, 236 Several studies investigated cognitive 
function in DMD.42, 237, 238 Most of them are descriptive, and generally the mean IQ is one 
standard deviation below the mean in the normal population.238, 239 Moreover the IQ can 
range from below 50 till 130 between DMD patients. Although longitudinal follow up 
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studies are lacking, the cognitive deficits do not seem to be progressive. The literature is 
not very consistent whether specific domains are affected, but executive function and 
verbal working memory are both involved.172 Besides, reading skills seems to be impaired 
in DMD.43, 44 Finally, behavioral problems like Attention Deficit and Hyperactivity Disorder 
(ADHD), Obsessive Compulsive Disorder (OCD) and autism spectrum  disorders are more 
prevalent in DMD.45, 46, 48 
To investigate the role of dystrophin in the brain a non-invasive tool is necessary. MRI is a 
safe and suitable method to investigate the brain in detail. Imaging of the brain in DMD is 
a subject of growing interest, but so far limited imaging studies of the brain in DMD have 
been performed. Different techniques have been used such as positron emission tomog-
raphy (PET), which showed region specific glucose hypometabolism,168 MRI showed fo-
cal changes in gray matter concentration170 and Magnetic resonance spectroscopy (MRS) 
showed metabolic changes in spe cific regions like the cerebellum and the temporo-pari-
eto region.167, 169 We decided to perform an explorative quantitative MRI study of the brain 
in DMD. In a large series of 30 DMD patients and 22 age-matched boys (aged 8-18 years) 
MRI images of the brain (T1-weighted and diffusion tensor images) were obtained. Also 
cognitive function and behavior were examined in all participants. Chapter 4 describes 
that the total brain volume and grey matter volume are smaller in DMD patients than in 
healthy controls. We also found that within the white matter parameters for microstruc-
ture were different compared to controls; this suggests that fiber density may be reduced, 
the permeability of cell membranes may be increased and/or the structure of the white 
matter may be less organized in DMD. The mean scores on neuropsychological tests were 
lower in DMD patients. Subgroup analyses showed that DMD patients with a mutation 
that predicts the lack of isoform Dp140, had significantly smaller brain volumes and grey 
matter volumes than healthy controls, while in DMD patients with a mutation that pre-
dicts presence of Dp 140 we did not find these differences compared to controls. This 
indicates that the dystrophin isoforms are important for cognitive functioning but also for 
development of the brain in infancy and early childhood. 
Chapter 5 describes and illustrates a serendipity we have found during the study on the 
brain in DMD. It concerns the cranium and the extracranial muscles. We observed that the 
skull of boys with DMD has a different shape compared to healthy age-matched controls. 
Whereas in controls the skull was ovoid shaped in DMD the circumference of the skull was 
rounder in the transverse plane, which could be determined quantitatively by eccentricity; 
the mean eccentricity was reduced in DMD. 
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In muscular dystrophies affected muscles may be hypertrophic. On visual inspection of the 
MRI images we observed that the temporal muscles in the DMD patients were clearly hyper-
trophic; the quantified thickness was indeed significantly increased compared to controls. 
One could speculate whether a different morphology of the skull has clinical consequenc-
es. We found a positive correlation between thickness of the temporal muscles and a 
rounder shape of the skull in DMD. We hypothesized that the different skull shape was 
secondary to weakness of the temporal muscles which are involved in masticatory func-
tion. The masticatory muscle group include masseter muscles, temporal muscles, medial 
and lateral pterygoid muscles. Impaired function of masticatory muscles seem to start 
at a young age as decreased bite force has been observed in DMD patients of 6 years 
and older199, 201 as well as dental malocclusion.240 Both can lead to impaired chewing. The 
morphology of the skull may be related to malocclusion as individuals with specific mor-
phology such as short lower face show a lower incidence of malocclusion and people 
with long-faced morphology have weak facial muscles and are predisposed to skeletal 
open bite.241, 242 In humans few intervention studies have been done and these lack ran-
domized controls; in young healthy adults bite force increased following training with 
systematic exercises using chewing gum.243 In a small study of 13 children (age 7-12 years) 
with long-faced morphology who had been practicing exercises with chewing gum for at 
least two hours a day during a year, bite force had increased compared to reference values 
of untrained age-matched children.241 More interesting, during this study the morphology 
of the orofacial structures (anterior mandibular rotation) had changed more than was ob-
served in an historical control group of untreated children of the same age. This suggests 
that changes in muscle force indeed can influence bony structures. Our study is the first 
to report a rounder skull shape in patients with DMD who are known to develop weak-
ness of the masticatory muscles. Muscle weakness might be related not only to impaired 
masticatory function and orofacial morphology but also to skull shape; moreover, it is not 
known whether the observed rounder skull shape is reversible or may become fixed in 
older children. In the latter case this may limit the restoration of orofacial function in DMD 
if new treatments become available that improve muscle strength. For clinical follow up it 
is important to anticipate that masticatory muscles could be involved early in the disease. 
In chapter 6 we investigated steroid treatment in Duchenne muscular dystrophy in a 
Dutch cohort. Steroid treatment extends the ambulant phase in DMD.123, 213, 244 In natural 
cohort studies boys with DMD became wheelchair-bound between 8.5-12 years.124 The in-
troduction of chronic steroid treatment in the mid 1990’s has prolonged ambulation for at 
least one year. The benefits are related to the dosage regimen of the steroids and should 
be weighed against the side effects.
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In the Netherlands guidelines for prednisone treatment were established in 2004.123 In 
the rehabilitation center De Trappenberg, however, young boys with DMD have been of-
fered prednisone since 1996 in an intermittent  scheme, in which 10 days prednisone 0.75 
mg/kg per day was alternated with 10 days without corticosteroids. In our study we ret-
rospectively analyzed data of a series of 35 DMD patients who have been treated with 
prednisone 0.75 mg/kg/day intermittently 10 days on/10 days off. Prednisone was started 
during the ambulant phase at age 3.5-9.7 years (median 6.5 years). The median period of 
treatment was 27 months (range 3-123). The median age at which ambulation was lost 
was 10.8 years (mean 10.9 years; 95% confidence interval 10.0-11.8). 
Possible side effects of chronic steroid treatment are weight gain, increased risk of osteo-
porosis and bone fractures. When treatment starts in childhood decreased body height 
and behaviour problems like hyperactivity have been reported, which all seem to be more 
pronounced in daily steroid regimes.225, 244, 245 In most studies evaluating steroids in DMD, 
weight gain is an important issue. During daily dose of 0.75 mg/kg/day weight gain > 10% 
was reported in three quarter of the patients.213, 214 In our study weight gain was found in 
one quarter of the patients, and more remarkably, only in boys after they got wheelchair 
bound. Seven of the eleven  patients that a reached body weight of +2SDS already had a 
body weight of +1SDS before start of prednisone. Therefore, this is probably a risk factor 
for excessive weight gain during steroid treatment. Moreover, we found that 40% of the 
patients in our study group did not have weight gain. Our data indicate that prednisone 
10 on/10 off has relatively few side effects and extends the ambulant phase with one year 
compared to historical controls. In contrast to the 10 day on/10 day off scheme that is cus-
tom in the Netherlands, elsewhere daily dosage of steroids is being used, which may be 
more successful in sustaining ambulant phase. In a recent observational study the median 
age for loss of ambulation was 12 years in boys on an intermittent steroid scheme and 14.5 
years in boys using daily steroid treatment.245 In clinical practice, usually treating physicians 
will discuss with the parents the expected advantages and disadvantages of daily versus 
intermittent treatment, which will result in shared decision making. Of note, a multicentre 
randomised controlled trial to search for the optimum steroid regimen is ongoing: FOR-
DMD (www.clinicaltrials.gov).  
In addition, it is reported that continuing steroids treatment in the non-ambulatory phase 
prevents scoliosis, reduces the need for spinal surgery and delays the progression of re-
spiratory function 225, 244, 246 Resuming, steroid treatment plays an important role in the 
standard treatment of boys with Duchenne and is recommended in the standards of care 
for DMD.16 Moreover, care for DMD will benefit from a multidisciplinary approach in which 
the different caregivers cooperate and interact as a team.16
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Future perspectives
During the last decade the organisation of care for patients with DMD has improved a lot 
in the Netherlands. For young boys with DMD and their parents multidisciplinary teams 
have been formed in different expert centres. More recently the process of transition for 
boys with DMD emerging adulthood is getting more attention.247 In contrast, the connec-
tion between the care for DMD and BMD is not always clear. This is somewhat surprising 
because clinical signs and symptoms of BMD resemble those of DMD. Besides, treatment 
strategies for DMD aim to improve muscle weakness by restoring the reading frame.105, 235, 
248 This would enable dystrophin expression and chronic treatment might result in a milder 
phenotype. Theoretically, a milder phenotype will be similar to a BMD phenotype. 
For a group (13%) of DMD patients, who have  a specific (nonsense) mutation that results 
in a prematurely stop in the production of normal dystrophin, a drug has been developed 
that repairs the effect of  premature stop codons but does not affect normal stop codons; 
this  enables dystrophin expression in DMD boys with nonsense mutations. 249 Recently 
this drug (called Translarna or ataluren) has got a positive opinion on a conditional market-
ing authorisation by the European Medicines Agency (www.ema.europa.eu). 
Recently reported but unpublished yet, is that the extended studies of the clinical trials 
with exon51 skipping show that long term, non-controlled, treatment longer than one 
year resulted in stable motor function in ambulant boys with DMD.
Moreover, new therapies that are being developed for DMD might also apply for BMD. 
Several studies now underway aim to improve muscle strength using drugs whose action 
is not-related to the mutation in the DMD gene. For example treatment with an analogue 
of co-enzyme Q
10  
idebenone, which aims to stabilize respiratory function, seems promis-
ing for patients with DMD who are not on steroid treatment; results are not published yet. 
Results of clinical studies in DMD with phosphodiestersase-5 inhibitors tadalafil/sildenafil 
are awaited; recently was found that sildenafil does not improve cardiac function in adult 
patients with dystrophinopathy neither was short term treatment with sildenafil in adult 
BMD patients effective on skeletal muscle performance.250, 251 Drug studies on metformine 
& L-citrulline, amino glycoside arbekacin-sulfate and pure tea analogue epicatechin are in 
the recruiting stage (www.clinicaltrials.gov). 
Also early detection of cardiac abnormalities and subsequent treatment with ACE inhibi-
tors and/or β-blockers may improve long term outcome in BMD and DMD. Clinicians could 
anticipate on upcoming new treatments for DMD and get expertise in the management 
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of care for the whole clinical spectrum of dystrophinopathies. Therefore if the care offered 
by multidisciplinary expert teams would cover all patients with a dystrophinopathy, care 
for both DMD and BMD may improve. In addition, multidisciplinary follow up for all dystro-
phinopathy patients would also facilitate that standardised clinical data on natural history 
of both disorders are registered prospectively.
The study described in chapter 4 is the first to report quantitative measures of brain vol-
umes in a large controlled series. Total brain and gray matter volumes are smaller in DMD, 
and this is more likely congenital or developmental than acquired, theoretically due to 
genetic nature of the disease and the fact that the cognitive deficit is apparently stable. 
We also observed that the intracranial volume and the skull size were proportional to the 
brain vol ume. In case of to acquired (cortical) atrophy a larger intracranial volume in rela-
tion to brain volume would have been expected.
Furthermore, we found a relation between brain volumes and the predicted absence of 
isoform Dp140 which is in agreement with previous studies on neuropsychological pro-
files in DMD patients with different mutations.50, 120 Nevertheless, the smaller gray matter 
volume and the less organized white matter structure might also be a consequence of 
having cognitive deficits and/or learning problems. If a young boy lacks dystrophin in the 
brain and has a learning problem, this might influence and delay brain maturation which 
might be expressed in a less organized white matter structure and in a smaller gray mater 
volume. Longitudinal analysis that starts at a very young age and includes measurements 
at multiple time points might clarify the evolution of brain volumes and of white mat-
ter structure during early development in DMD boys, compared to healthy age-matched 
controls. However, logistically it will be very problematic to perform MRI scans in very 
young children, as they usually need sedation to lay still in a scanner. Since verbal and lan-
guage skills seem to improve in older DMD boys, particularly those of 14 years and older,42 
longitudinal follow up with renewed MR imaging and neuropsychological testing of the 
participants of our study may also be informative. A  follow up study has started.
Furthermore, imaging techniques such as MRI and functional MRI (fMRI) are excellent tools 
to observe and quantify brain structures parameters longitudinally. The neuropsycholog-
ical profile is a heterogeneous aspect of DMD and its relation to dystrophin in the brain is 
probably complex. It would be very informative if brain activity could be visualized during 
execution of specific tasks like reading or information processing.
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The diagnostic work up in dystrophinopathies is sometimes simple but can be challeng-
ing, especially if the phenotype is not typical. Especially in BMD the clinical symptoms are 
known to be variable and the differential diagnosis may be large in adult patients; more-
over the prevalence of BMD is significantly lower than of DMD. Accordingly, it is possible 
that in BMD patients with mild symptoms the diagnosis is missed. It is not likely that exten-
sive work up including muscle biopsy, immunoblotting and/or DNA analysis is performed 
in all cases with mild symptoms such as exertional induced muscle cramps and myalgia 
or with asymptomatic hyperCKemia. Myalgia and cramps are frequently occurring and 
non-specific symptoms for which many patients are referred to outpatient clinics.252, 253 
HyperCKemia can occur in neuromuscular as well as non-neuromuscular disorders, and 
is also known as an idiopathic condition.53, 84 Besides, mild BMD has been described with 
normal CK56, 254, 255 and the prevalence of BMD with mild symptoms is probably higher than 
is yet known.22, 256 Immunohistochemical studies on dystrophin may be normal in BMD.144, 
257-259 Western blotting is more sensitive to detect disturbed dystrophin production in BMD 
but is technically more difficult, costly and reserved to specialized laboratories to which 
fresh or frozen muscle tissue has to be sent. 
Indeed the extent of the diagnostic work up in cases with mild symptoms or only hy-
perCKemia should be personalised. In daily practice there will be a trade-off between 
the benefits and the discomfort of a muscle biopsy, the costs of diagnostic procedures 
and the consequences of the expected results. A prospective study is needed to find out 
which cases with mild symptoms and/or hyperCKemia will benefit from extensive work up 
including Western blot analysis of muscle tissue and DNA analysis including sequencing.
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Duchenne spierdystrofie (DMD) en Becker spierdystrofie (BMD) zijn als spiegelbeelden: 
gelijkend maar toch verschillend. Gemeenschappelijke kenmerken zijn: kuithypertrofie, 
spierzwakte in de spieren van bovenbenen en later ook in de onderbenen en boven-
armen, verhoogde spiegel van creatinekinase (CK) in het bloed en cardiomyopathie. De 
aandoeningen zijn verschillend van elkaar betreft het beloop, prognose en therapeuti-
sche mogelijkheden. In genetisch opzicht worden beide aandoeningen veroorzaakt door 
een mutatie op het DMD gen, dat zich op het X-chromosoom bevindt. De leesraamhypo-
these houdt in dat als een mutatie het leesraam verstoort, dystrofine ontbreekt. Dit leidt 
tot een ernstig verlopend ziektebeeld, Duchenne spierdystrofie. Blijft ondanks de mutatie 
het leesraam intact (in-frame) dan leidt dit tot een milder fenotype, genaamd Becker spier-
dystrofie. Op het eerste gezicht lijkt heterogeniteit meer van toepassing op BMD dan op 
DMD, omdat bij BMD de aandoening ernstig maar ook zeer mild kan verlopen.
In hoofdstuk 1 worden de verschillende klinische fenotypen van dystrofinopathieën be-
schreven en diagnostische overwegingen besproken. Vuistregel is dat bij een dystrofi-
nopathie het serum CK is verhoogd. Omgekeerd is er bij patiënten met een verhoogd CK 
een uitgebreide lijst van differentiële diagnoses. Daarom worden diagnostische algoritmes 
voor asymptomatische en weinig symptomatische hyperCKemie uitgebreid besproken en 
wordt in een schematisch overzicht weergegeven welke neuromusculaire aandoeningen 
zich kunnen presenteren met hyperCKemie. Het diagnostische proces bij patiënten met 
een spierdystrofie wordt idealiter voltooid met een moleculair-genetische diagnose, dat 
wil zeggen dat ook de DNA mutatie bekend is. Informatie over de DNA mutatie is belang-
rijk om de volgende drie redenen: het helpt om patiënten beter te classificeren, waarop de 
zorg ook kan worden toegespitst, ten tweede om erfelijkheidsadvisering aan familieleden 
te kunnen aanbieden en tot slot om toekomstige behandelingen voor patiënten met een 
dystrofinopathie goed te kunnen implementeren.
Deel 1 van dit proefschrift gaat over BMD en twee studies worden gepresenteerd. 
De studie uit hoofdstuk 2 beschrijft dat bij BMD de mutatie soms veel later gevonden 
wordt dan het moment waarop verwijzing plaatsvindt. Voor deze studie werd een cohort 
van 185 patiënten opnieuw bekeken; het betrof patiënten voor wie DNA-onderzoek naar 
mogelijke BMD was aangevraagd in de periode 1985–1995. Het gen voor dystrofinopathie 
(DMD gen) was het eerste gen dat ontdekt werd en beschikbaar kwam voor diagnostische 
bepaling bij patiënten bij wie de clinicus dacht aan een spierdystrofie. In deze eerste pe-
riode van DNA-onderzoek van het DMD gen was de standaardanalysemethode screenen 
naar deleties en duplicaties. In 70% van de patiënten met een dystrofinopathie is er sprake 
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van een deletie of een duplicatie. Voorts heeft 10-15% van de patiënten met de dystrofi-
nopathie dat bij patiënten een puntmutatie in het DMD gen; nieuwe technieken om deze 
kleine mutaties op te sporen zijn het laatste decennium ontwikkeld. Als geen deleties of 
duplicaties worden gevonden bij de standaardanalyse kan het onderzoek tegenwoordig 
worden uitgebreid met sequentie-analyse om kleine mutaties te vinden. Terugkijkend is 
het dus mogelijk dat bij patiënten die lang geleden verwezen zijn voor diagnostiek naar 
dystrofinopathie en bij wie destijds geen mutatie was gevonden de diagnose BMD is ge-
mist omdat zoeken naar kleine mutaties nog niet mogelijk was. 
 
De onderzoeksvraag was of diagnostische opbrengst kan worden verbeterd door alsnog 
sequentie-analyse toe te passen bij de groep patiënten voor wie in deze vroege perio-
de DNA-onderzoek was aangevraagd. Alle dossiers van de patiënten, die in de periode 
1985–1995 waren verwezen voor diagnostiek naar mogelijke BMD en bij wie nog geen 
diagnose was gesteld, werden opnieuw bekeken; als de klinische informatie op het aan-
vraagformulier van destijds nog steeds paste bij mogelijk Becker spierdystrofie en er nog 
DNA bewaard was, werd dit opnieuw geanalyseerd.
Bij 31 van de 79 patiënten zonder diagnose kon DNA opnieuw worden geanalyseerd. Er 
zijn acht verschillende mutaties gevonden in deze groep, waarvan vier niet eerder gepu-
bliceerd (novel). Van alle patiënten met een novelmutatie konden we nieuwe klinische 
informatie krijgen, 15 – 25 jaar na initiële verwijzing. In drie van de patiënten is de mutatie 
pathogeen en leidt tot een frameshift; twee van hen hadden progressieve limb girdle 
spierzwakte en bij een patiënt was er sprake van een somatische mozaïek, hij blijkt asymp-
tomatisch. Ook was er een patiënt met een novel missense mutatie; hiervan is niet zeker 
of deze pathogeen is. Deze patiënt had milde spierklachten, forse kuiten en hyperCKemie, 
wat ook kan passen bij een milde vorm van BMD.
Een late diagnose kan ook na jaren nog relevant zijn omdat dit duidelijkheid geeft aan de 
betrokkenen, en zij verwezen kunnen worden naar de cardioloog voor onderzoek naar 
betrokkenheid van de hartspier; in dat geval is vaak medicatie gewenst. Daarnaast kunnen 
vrouwelijke familieleden worden getest op draagsterschap als de mutatie bekend is. 
Het vinden van mutaties en daarmee genetisch bevestigen van de diagnose BMD werd 
bereikt omdat nieuwere technieken werden toegepast op bewaard materiaal. Essentieel 
hiervoor is dat bij de aanvraag voor diagnostiek klinische informatie wordt gegeven opdat 
de moleculair- geneticus kan beoordelen bij welke patiënten vervolgdiagnostiek zinvol is 
indien er nieuwe diagnostische inzichten zijn. Helaas moesten we 22 patiënten van dit re-
trospectief bekeken cohort uitsluiten omdat er geen klinische informatie beschikbaar was 
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op het aanvraagformulier. Een aanbeveling uit deze studie is dat samenwerking tussen 
clinicus, moleculaire geneticus en klinisch geneticus de diagnostische uitkomst kan verbe-
teren bij patiënten zonder diagnose. Hiervoor is het dus belangrijk dat klinische gegevens 
van patiënten worden gedeeld.
Het klinische fenotype Becker spierdystrofie is niet alleen interessant vanwege de hetero-
geniteit maar ook omdat dit fenotype als model kan dienen wanneer nieuwe therapieën 
voor Duchenne spierdystrofie worden ontwikkeld waarbij dystrofine wordt aangemaakt 
in de spieren bij DMD patiënten. Bij patiënten met spierdystrofie en een deletie van een 
of meer exonen die het leesraam verstoort, kan door een exon te skippen de deletie ver-
anderen van out-of-frame (DMD fenotype) naar in-frame (BMD fenotype); Bij in-frame is 
het leesraam, dat de DNA code afleest, hersteld waardoor in de spiercel een verkorte vorm 
van het eiwit dystrofine geproduceerd kan worden. Exonskipping geschiedt via antisense 
oligonucleotiden (AONs); aangezien er bij DMD veel verschillende mutaties voorkomen 
zullen er dus verschillende AONs moeten worden ontwikkeld die ieder gericht zijn op een 
specifieke plaats op het dystrofine-gen. Na chronische toediening van een AON, dat een 
specifiek exon skipt, kunnen de spiercellen dystrofine gaan produceren. Dit dystrofine is 
vergelijkbaar met het gedeeltelijk functionele dystrofine van patiënten met Becker spier-
dystrofie die van nature een deletie hebben die ook het target exon van de AON therapie 
omvat. De eerste behandeling die in klinische trials werd getest was exonskipping van 
exon 51.
In hoofdstuk 3 beschrijven we de fenotypes en de klinische follow-up van de twee families 
met Becker spierdystrofie die in Nederland bekend zijn met een mutatie inclusief exon 
51. Dit fenotype zou model kunnen zijn voor patiënten met Duchenne spierdystrofie die 
behandeld worden met een AON die exon 51 skipt, hetgeen tot nu toe alleen in studie-
verband is geschied. 
Het beloop van de aandoening van de drie patiënten uit deze families was zeer mild. 
De index patiënt uit de eerste familie werd gezien door een neuroloog op de leeftijd 
van 14 jaar omdat hij veel last had van krampen tijdens inspanning sinds zijn kinderleef-
tijd. Zijn CK spiegel in het bloed was 50 maal verhoogd en hij had een in-frame muta-
tie deletie van exonen 45–51 van het DMD gen. Zijn grootvader van moederszijde had 
ook krampen van kinderleeftijd tot jong volwassen leeftijd en hij had dezelfde mutatie. 
Beide mannen zijn onderzocht op volwassen leeftijd. Geen van beiden had spierzwakte. 
De grootvader was asymptomatisch op 78-jarige leeftijd en had een normaal CK in het 
bloed. Kleinzoon had forse kuiten op de leeftijd van 46 jaar en zeer geringe inspannings-
gebonden spierklachten en daarbij een marginaal verhoogde CK spiegel in het bloed.
c-straathof-binnenwerk_zw_100gprint_3mmbleed-versie2.indd   113 15-9-2014   13:25:46
114
Chapter 7
In de tweede familie was de indexpatiënt acht jaar toen hij verwezen werd naar een kin-
derarts vanwege hyperactief gedrag. Bij routine laboratoriumonderzoek werden hoge CK 
spiegels gevonden. DNA-onderzoek toonde een in-frame deletie van de exonen 50–51. 
Toen hij opnieuw werd onderzocht op de leeftijd van veertien jaar had hij geen spier-
zwakte. Sporadisch had hij inspanningsgebonden spierkrampen. 
Het zeer milde beloop in beide BMD families, met een mutatie die exon 51 omvat, kan 
veelbelovend zijn voor de patiënten met Duchenne spierdystrofie die in aanmerking ko-
men voor behandeling met exon 51 skipping.
Deel 2 van het proefschrift gaat over Duchenne spierdystrofie. 
Hierbij zijn cognitie en gedrag heterogene aspecten. Naast de bekende spierzwakte die 
bij jongens vaak al vanaf de kleuterleeftijd optreedt, heeft een deel van de patiënten met 
DMD een lager IQ en/of leerproblemen, wat in zeldzame gevallen ook de eerste uiting 
van de aandoening kan zijn. Deze cognitieve stoornissen duiden erop dat ook het cen-
traal zenuwstelsel is betrokken bij DMD hoewel de oorzaak en het mechanisme nog niet 
zijn opgehelderd. Het is bekend dat dystrofine, dat zeer belangrijk is voor stabiliteit van 
de spiercelmembraan en daardoor voor de functie van spieren, ook expressie heeft in 
andere weefsels waaronder de hersenen. Naast transcriptie van het volledige dystrofine 
eiwit Dp427 zijn er ook verschillende kortere isoforms, waarvan de promotor meer distaal 
is gelokaliseerd op het DMD gen. Deze isoforms, Dp260, Dp 140, Dp 116 en Dp 71 komen 
in diverse weefsels tot expressie (zie ook figuur 3 op pagina 31 ). Bijvoorbeeld, van Dp140 
en Dp 71 is bekend dat deze isoforms in foetaal hersenweefsel tot expressie komen; waar-
schijnlijk zijn deze belangrijk voor cognitieve functies. Echter, wat de specifieke functie 
is van deze isoforms in de hersenen, is niet bekend. Patiënten met DMD en een ernstige 
cognitieve beperking hebben vaker een mutatie in het distale deel van het DMD gen 
waardoor Dp 140 en Dp 71 ontbreken.
 
In eerdere studies is cognitieve functie bij DMD meestal onderzocht door middel van 
descriptief neuropsychologisch onderzoek; op groepsniveau is het gemiddelde IQ een 
standaarddeviatie onder het gemiddelde IQ van de normale populatie. De variatie van 
het gemeten IQ bij DMD is echter breed met een range van 50-130. De cognitieve pro-
blemen bij DMD lijken niet progressief, echter longitudinaal onderzoek hiernaar is niet 
verricht. Uit de literatuur blijkt dat meerdere domeinen betrokken zijn waaronder exe-
cutieve functies en het verbale werkgeheugen. Ook is de leesvaardigheid vaak minder 
bij jongens met DMD. Gedragsstoornissen zoals attention deficit en hyperactivity disor-
der (ADHD), obsessief–compulsieve stoornis (OCS) en stoornis in het autismespectrum 
worden vaker gezien bij jongens met DMD. Om de rol van het dystrofine in het brein 
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te onderzoeken is een niet-invasieve onderzoeksmethode nodig. MRI is een veilige en 
goede methode om de hersenen in detail te onderzoeken. Eerdere studies, meestal met 
kleine series patiënten, toonden aanwijzing voor een veranderd metabolisme bij DMD. 
Verschillende technieken zijn gebruikt zoals positron emission tomografie (PET), waarbij 
scans een veranderd glucose metabolisme aantoonden in specifieke regio’s. Bij MRI stu-
dies werden op scans lokale veranderingen in de grijze stof gevonden en bij magnetic 
resonance spectroscopie (MRS) werden metabole veranderingen in het cerebellum en de 
tempero–pariëtale gebieden gevonden. 
Onze onderzoeksgroep is gestart met een exploratieve kwantitatieve MRI studie naar de 
rol van dystrofine in het brein bij DMD. Een grote groep van 30 patiënten met DMD en een 
groep van 22 leeftijd gematchte controles (leeftijd 8-18 jaar) werden geïncludeerd. MRI 
scans (T 1-gewogen opnames en diffusion tensor image (DTI) opnames) werden gemaakt 
en alle deelnemers kregen neuropsychologisch onderzoek. Tevens werden vragenlijsten 
voor gedrag ingevuld. 
In hoofdstuk 4 beschrijven we dat het totale breinvolume en het volume van de grijze stof 
kleiner is in DMD patiënten dan in gezonde controles. Ook vonden we dat microstructuur 
in de witte stof verschillend was vergeleken bij controles. Dit suggereert ten eerste dat de 
vezeldichtheid in de witte stof bij DMD verminderd is en ten tweede -mogelijk- dat de per-
meabiliteit van de celmembranen verhoogd is of dat de organisatie van de witte stof minder 
goed ontwikkeld is. De gemiddelde score op de neuropsychologische testen was lager in 
de groep patiënten DMD. In een subgroepanalyse werd gevonden dat bij patiënten bij wie 
de mutatie voorspelt dat isoform Dp 140 ontbreekt, het volume van de hersenen en van de 
grijze stof significant kleiner was ten opzichte van gezonde controles. In DMD patiënten met 
een mutatie die aanwezigheid van Dp 140 voorspelt vonden we dit verschil ten opzichte 
van controles echter niet. Dit kan betekenen dat dystrofine isoforms inderdaad belangrijk 
zijn voor het cognitief functioneren en ook voor de vroege ontwikkeling van het brein.
Hoofdstuk 5 beschrijft een serendipiteit die wij tegenkwamen bij de MRI breinstudie in 
DMD. Het betreft de schedel en de spieren die aan de buitenzijde van de schedel aan-
hechten. Wij deden de observatie dat de vorm van de schedel van jongens met Duchenne 
anders is vergeleken met gezonde leeftijdsgenoten. In jongens zonder spierziekte is de 
schedel ovaalvormig en in DMD blijkt dat de omtrek van de schedel ronder is in het trans-
versale vlak. Een maat voor ronding is eccentriciteit en bij jongens met DMD was de ge-
middelde eccentriciteit verlaagd. Daarnaast zagen we bij visuele beoordeling van de MRI-
plaatjes dat de musculus temporalis die ter hoogte van de slapen aanhecht, aan beide 
zijden hypertrofisch is, dat wil zeggen dikker. Bij kwantificeren was de dikte van deze spier 
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inderdaad groter bij DMD patiënten vergeleken met gezonde controles.
Het is niet zeker of een andere schedelvorm klinisch relevant is. We vonden een positieve 
correlatie tussen dikte van de temporalis spieren en een rondere schedelvorm bij jon-
gens met DMD. Een hypothese is dat de verandering van de schedelvorm secundair is 
aan zwakte van de temporalis spieren, die deel uitmaken van de kauwspieren. De groep 
kauwspieren omvat de musculus masseter, de musculus temporalis en de mediale en 
laterale musculus pterygoideus, alle zowel links als rechts aangelegd. Waarschijnlijk zijn 
de kauwspieren al vroeg aangedaan bij DMD. Eerder werd gevonden dat de bijtkracht 
verminderd is en dat de boven- en onderkaak niet goed op elkaar sluiten (dentale ma-
locclusie) bij patiënten met DMD van de leeftijd van zes jaar. Beide zijn van belang om 
goed te kunnen kauwen. Eerder is gevonden dat er een relatie lijkt te bestaan tussen 
de schedelvorm en dentale malocclusie ook zonder onderliggende spierziekte; mensen 
met een langwerpige gezichtsvorm hebben vaker zwakkere aangezichtspieren en heb-
ben een groter risico op een open beet, terwijl mensen met een kort breder gezicht 
minder kans hebben op deze malocclusie. Interventiestudies zijn echter beperkt beschik-
baar en hierbij ontbreken controlegroepen. In een studie werd gevonden dat bij jonge 
gezonde volwassenen de bijtkracht verbeterde na systematisch dagelijks oefenen met 
harde kauwgom. In een andere serie met 13 kinderen (leeftijd 7-12 jaar) met langwerpig 
gezichtsvorm, die trainden met kauwgom tenminste twee uur per dag gedurende een 
jaar, was de bijtkracht groter vergeleken met de referentiewaarden bij ongetrainde leef-
tijdsgenoten; opmerkelijk veranderden de vorm en de positie de kaak en gerelateerde 
structuren (anterior mandibular rotation) ten opzichte van een historische controlegroep. 
Dit suggereert dat wanneer spierkracht verandert, de stand van botstructuren beïnvloed 
kan worden. 
De studie uit hoofdstuk 5 is de eerste publicatie van een rondere schedelvorm in DMD pa-
tiënten, van wie bekend is dat zij op enig moment ook zwakte van de kauwspieren krijgen. 
Een mogelijke verklaring zou kunnen zijn dat spierzwakte niet alleen gerelateerd is aan 
minder kauwfunctie en veranderde kaakvorm maar ook verandering geeft van de sche-
delvorm. Uit onze observationele studie die op één moment een meting heeft verricht 
en waar meten van kracht (functie) niet tot de studiedoelen hoorde, kan niet de conclusie 
worden getrokken dat zwakte de oorzaak is van een rondere schedelvorm. Verder is niet 
bekend of een rondere schedelvorm reversibel is ofwel dat deze gefixeerd is bij kinderen 
die uitgegroeid zijn. Als het laatste het geval is, zou een veranderde schedelvorm, die 
niet reversibel is, verbetering van kauwfunctie bij DMD kunnen belemmeren als nieuwe 
behandelingen beschikbaar komen die spierkracht kunnen verbeteren. Voor clinici is het 
belangrijk in de begeleiding en behandeling van patiënten met DMD erop te anticiperen 
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dat kauwfunctie mogelijk vroeg in de ziekte is aangedaan.
In hoofdstuk 6 gaat over corticosteroïdbehandeling bij DMD patiënten. Behandeling met 
steroïden kan de loopfase (ambulante fase) bij jongens met DMD verlengen. In historische 
cohortstudies was gevonden dat gemiddelde leeftijd waarop jongens met DMD rolstoel-
gebonden werden lag tussen de 8.5-12 jaar. Na de introductie van chronische steroïdbe-
handeling werd de ambulante fase met tenminste een jaar verlengd. Het gunstige effect 
van steroïden moet worden afgewogen tegen de bijwerkingen. In Nederland zijn richtlij-
nen voor steroïden geïmplementeerd in 2004. In het revalidatie centrum De Trappenberg 
in Huizen werden jonge kinderen met DMD reeds behandeld met prednison sinds 1996; 
het behandelschema was intermitterend: 10 dagen prednison 0.75 mg/kilogram/dag 
gevolgd door 10 dagen zonder steroïden. In de studie uit hoofdstuk 6 hebben we re-
trospectief van serie van 35 DMD patiënten beschreven die met prednison zijn behan-
deld. Prednison was gestart gedurende de ambulante fase op de leeftijd van 3.5-9.7 jaar 
(mediaan 6.5 jaar). De mediane periode van behandeling was 27 maanden (range 3-123). 
De mediane leeftijd waarop loopfunctie stopte pas 10.8 jaar (gemiddeld 10.9 jaar; 95% 
betrouwbaarheidsinterval 10.0-11.8)
Mogelijke bijwerkingen van chronische behandeling met steroïden zijn gewichtstoena-
me, verhoogd risico op osteoporose en botfracturen. Ook is beschreven dat chronische 
steroïdbehandeling, gestart in de kinderleeftijd, kan leiden tot korte lichaamslengte en 
tot gedragsproblemen zoals hyperactiviteit; beide lijken met name gerelateerd aan do-
seringsschema’s waarbij steroïden dagelijks worden gebruikt. Eerder is gerapporteerd dat 
dagelijks gebruik van prednison 0.75 mg/kilogram dag kan leiden tot gewichtstoename 
van meer dan 10% bij driekwart van de patiënten. Echter in onze studie werd gevonden 
dat gewichtstoename optrad bij een kwart van de patiënten, en opmerkelijk, alleen in pa-
tiënten die rolstoelgebonden waren. Bovendien trad een lichaamsgewicht van +2 SDS op 
bij zeven van de 11 patiënten die reeds vóór start prednison een lichaamsgewicht hadden 
van +1 SDS. Waarschijnlijk is een risico voor het ontwikkelen van excessief overgewicht de 
aanwezigheid van mild overgewicht vóór de start van prednison. Daarentegen had 40% 
van de patiënten in onze studie geen overgewicht. Intermitterend prednison, 10 op/10 
af, lijkt gepaard te gaan met relatief weinig bijwerkingen. Momenteel wordt het intermit-
terende schema veel gebruikt in Nederland bij patiënten met DMD. Elders wordt vaak 
dagelijkse dosering steroïden voorschreven; hiermee wordt ambulante fase waarschijnlijk 
meer verlengd. In een recente observationele studie uit 2013 werd gevonden dat de me-
diane leeftijd voor verlies van ambulantie 12 jaar was bij intermitterend steroïdengebruik 
en 14.5 jaar bij jongens die het dagelijks gebruikten. In de dagelijkse klinische praktijk zal 
de behandelend arts met de ouders de te verwachten voordelen en nadelen van da-
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gelijks prednison gebruik bespreken en kunnen zij gezamenlijk een keuze maken voor 
intermitterend of dagelijks corticosteroïdengebruik. Overigens loopt er op dit moment 
een multicenter gerandomiseerd onderzoek waarin dagelijks en intermitterend gebruik 
wordt vergeleken: FOR-DMD (www.clinicaltrials.gov).
Tevens zijn er aanwijzingen dat het voortzetten van steroïdbehandeling in de non-ambu-
lante fase ernstige scoliose kan voorkomen waardoor minder vaak een grote rugopera-
tie noodzakelijk is; waarschijnlijk vertraagt prednison ook de achteruitgang van de long-
functie en van de hartfunctie. Samenvattend spelen steroïden een belangrijke rol in de 
standaardbehandeling van jongens met DMD en wordt behandeling aanbevolen in de 
behandelrichtlijnen voor DMD. Daarnaast dient de zorg bij DMD worden gegeven door 
een multidisciplinair werkend team.
 
reflecties op de toekomst
In de laatste decade is een organisatie van zorg voor patiënten met DMD in Nederland 
sterk verbeterd. Voor kinderen met DMD en hun ouders zijn er multidisciplinaire behan-
delteams in verschillende expertisecentra. Meer recentelijk gaat de aandacht naar verbe-
tering van het proces van transitie voor jongens met DMD op weg naar volwassenheid. 
Verrassend is dat de zorg voor DMD en BMD weinig overlap heeft. Immers beide aandoe-
ningen hebben vergelijkbare klinische symptomen hoewel beloop van de ziekte en de 
prognose verschillend is. Er wordt toegewerkt naar een gerichte behandeling voor DMD 
om de spierzwakte te verbeteren door productie van dystrofine in de spier mogelijk te 
maken. Het beoogd effect is minder snelle achteruitgang van spierzwakte. Als dit lukt, 
en het ziekteproces milder verloopt, zullen de symptomen en problemen lijken op het 
beloop van de aandoening bij BMD. 
Voor een deel van de patiënten (13%) met DMD die een specifieke mutatie heeft, waar-
bij de mutatie leidt tot een voortijdig stopcodon, dat zorgt dat productie van dystrofine 
voortijdig gestopt wordt, is er recente een doorbraak; een medicijn dat het effect van een 
voortijdig stopcodon teniet doet, genaamd Translarna of ataluren, is na fase 3 klinische 
trial door de autoriteiten voorwaardelijk goedgekeurd om toe te passen bij ambulante pa-
tiënten met DMD en een specifieke stopcodonmutatie. Ook de (nog niet gepubliceerde)
resultaten van lange termijnbehandeling (langer dan 1 jaar) met AONs die exon 51 skip-
pen zijn veelbelovend aangezien een groot deel van de behandelde ambulante patiënten 
stabiele scores heeft voor motorische functies, met name loopfunctie.
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Daarnaast worden er therapieën ontwikkeld voor DMD die ook van toepassing kunnen 
zijn bij BMD. Diverse middelen worden onderzocht waarvan de werking niet is gerela-
teerd aan de mutatie in het DMD gen. Bijvoorbeeld het middel idebenone, een analoog 
van co-enzym Q10, lijkt een gunstig effect te hebben op de longfunctie van jongens met 
DMD die geen prednison gebruiken; de resultaten van deze studie moeten nog gepubli-
ceerd worden. Klinische studies in DMD patienten met fosfodiesterase-5remmers, tadalafil 
en sildenafil, zullen de komende tijd hun resultaten bekend maken. Andere studies wer-
ven nu patiënten voor deelname: studies naar het effect van metformine en L-citrulline, 
aminoglycoside Arbekan-sulfaat en naar puur thee analoog epicatechin.
Tenslotte is het voor de lange termijn behandeling van belang dat hartproblemen vroeg-
tijdig worden opgespoord en zonodig behandeld worden met ACE-remmers en/of bèta-
blokkers die de lange termijn uitkomst van hartfunctie kunnen verbeteren zowel in BMD 
als DMD. Door de zorg voor beide aandoeningen gecombineerd en multidisciplinair te or-
ganiseren kunnen behandelaars expertise krijgen in het hele klinische spectrum van dys-
trofinopathie en kan men anticiperen op toekomstige therapieën voor DMD. Uiteindelijk 
zullen zowel patiënten met BMD als DMD hiervan profiteren. Ook is het zinvol om het 
beloop van de aandoening bij patiënten met DMD en BMD prospectief en in gestandaar-
diseerde vorm vast te leggen gedurende de multidisciplinaire follow-up.
De studie beschreven in hoofdstuk 4 is de eerste die in een grote serie patiënten met DMD 
kwantitatieve metingen heeft gedaan naar breinvolumes en deze heeft vergeleken met 
controles. De hypothese is dat de gevonden kleinere volumes van totale hersenen en van 
grijze stof waarschijnlijk al in aanleg aanwezig zijn of ontstaan tijdens de ontwikkeling van 
het jonge kind; dit vanwege het feit dat DMD een genetische aandoening betreft waarbij 
dystrofine in aanleg ontbreekt en het feit dat de cognitieve problemen stabiel blijken. 
Bovendien vonden wij een relatie tussen het volume van de hersenen en de voorspelde 
afwezigheid van isoform Dp 140 hetgeen in overeenstemming is met voorgaande studies 
omtrent neuropsychologische profielen in DMD patiënten met verschillende mutaties. 
Overigens is niet uitgesloten dat een kleiner volume van de grijze stof en minder georgani-
seerde witte stofstructuur gevolgen zijn van het hebben van cognitieve stoornissen en/of 
leerproblemen. Om de evolutie van het volume van de hersenen en van de structuur van 
de witte stof van jongens met DMD goed te bestuderen zijn meerdere meetpunten ge-
wenst inclusief een eerste meting op zeer jonge leeftijd tijdens de vroegste ontwikkeling. 
In praktische zin is dit echter logistiek lastig omdat zeer jonge kinderen voor het uitvoeren 
van een MRI scan gesedeerd moeten worden om stil te blijven liggen. Er zijn aanwijzingen 
dat de verbale en de taalvaardigheden juist verbeteren bij oudere jongens met DMD, in 
het bijzonder jongens boven 14 jaar en ouder; een tweede meetpunt door middel van 
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herhalen van de MRI scans en van het neuropsychologisch onderzoek bij dezelfde groep 
deelnemers uit onze studie kan informatief zijn. Een follow-upstudie is gestart. Daarnaast 
kan het visualiseren van hersenactiviteit tijdens uitvoerende en/of leertaken zoals lezen 
en informatieprocessing zinvol zijn. Andere MRI technieken zoals functionele MRI (f MRI) 
kunnen een geschikte meetinstrument zijn om verschillende structuren in de hersenen 
verder te observeren en metingen te kwantificeren.
Tot slot, het diagnostisch proces bij dystrofinopathie is soms eenvoudig maar kan ook moei-
lijk zijn, met name als het fenotype niet typisch is. Juist bij volwassen patiënten met BMD 
variëren de klinische symptomen van mild tot ernstig en de lijst van differentiële diagnoses 
kan lang zijn; bovendien is de prevalentie van BMD significant lager dan van DMD. Mogelijk 
wordt de diagnose BMD ook gemist bij patiënten met milde symptomen. Sporadische pa-
tiënten met milde symptomen zoals inspanningsgebonden krampen, spierpijn of asymp-
tomatisch hyperCKemie zullen niet allemaal een uitgebreide diagnostische work-up krij-
gen naar een mogelijke dystrofinopathie inclusief spierbiopsie, met Western blotting en/
of DNA-onderzoek. Spierpijn en spierkrampen zijn veel voorkomende symptomen en bo-
vendien niet specifiek voor dystrofinopathie; hoewel hyperCKemie kan optreden als enige 
uiting van een milde dystrofinopathie kan dit ook optreden bij infecties of als bijwerking 
van medicatie en tevens komt hyperCKemie idiopathisch voor. Omgekeerd zijn er pati-
enten beschreven die een normaal CK hadden en toch een milde BMD; waarschijnlijk is 
de prevalentie van BMD met milde symptomen dan ook hoger dan tot nu toe bekend. 
Aanvullend onderzoek hoeft niet afwijkend zijn, inclusief immunohistochemisch onder-
zoek (dystrofine-kleuring op coupes van spierweefsel). Western blotting op spierweefsel is 
meer sensitief om een gestoorde dystrofine productie bij BMD op te sporen. Technisch ge-
zien is dit moeilijker dan immunohistochemisch onderzoek en ook kostbaarder, en wordt 
over het algemeen alleen verricht in gespecialiseerde laboratoria. In hoeverre de diagnosti-
sche work-up bij patiënten met milde klachten en/of alleen hyperCKemie uitgebreid moet 
zijn zou per patiënt moeten worden bekeken. In de dagelijks praktijk zal de behandelaar 
een afweging maken tussen de opbrengst van aanvullend onderzoek en de ongemakken 
of complicaties van een spierbiopsie; maar ook de kosten van de procedure en de conse-
quentie van gevonden resultaat zouden moeten worden meegenomen. Een prospectieve 
studie kan behulpzaam zijn om duidelijk te krijgen welke patiënten met milde symptomen 
en/of hyperCKemie baat hebben van uitgebreide work-up inclusief Western blot analyse 
van spierweefsel en DNA-onderzoek inclusief sequensen.
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Neuromuscular diagnoses that can present with hyperCKemia and 
mild symptoms 53, 84, 87 
TABle A  CK level and symptoms  
   page 126-129 >>
TABle B  Signs and diagnostic tools 
   page 130-133 >>
AD: autosomal dominant; 
AR: autosomal recessive; 
APR: Achilles tendon reflex; 
BMD: Becker muscular dystrophy; 
CK: creatine kinase; 
DMD: Duchenne muscular dystrophy;  
EMG: electromyography; 
ER: exercise related; 
ESR: erythrocyte sedimentation rate; 
IHC: immunohistochemical staining of muscle tissue; 
LGMD: limb girdle muscular dystrophy; 
MMD: Miyoshi-type muscular dystrophy; 
PA: histopathological analysis; 
RRF: ragged red fibers; 
WB: Western Blot analysis of muscle tissue; y: year
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table a: CK level and symptoms - continued
 
A
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Dit proefschrift was niet tot stand gekomen zonder de bereidheid van patiënten om mee 
te werken aan de studies. Ik wil hierbij de jongens met Duchenne spierdystrofie en hun 
ouders bedanken voor hun deelname aan de MRI brein studie, hun geduld en hun altijd 
goede humeur.
Voor de retrospectieve studies naar Becker spierdystrofie waren patiënten bereid, soms 
jaren nadat zij voor het eerst een neuroloog bezocht hadden, opnieuw hun verhaal te 
vertellen en zich te laten onderzoeken. Mijn waardering hiervoor is groot. 
Veel respect verdient de patiëntenvereniging Duchenne Parent Project en haar voorzitter 
Elizabeth Vroom om de niet aflatende inzet voor de patiënten met Duchenne spierdystro-
fie en de ondersteuning van wetenschappelijke studies naar dystrofinopathie. 
Een van de leukste kanten van het doen van onderzoek is voor mij het contact en de 
samenwerking met collega’s van andere afdelingen. Ik was vanaf het begin betrokken 
bij het MRI breinonderzoek bij Duchenne spierdystrofie. Het is fantastisch om te zien 
hoe dit project zich ontwikkeld heeft met fulltime inzet van Nathalie Doorenweerd en 
onder constructieve leiding van met name dr. Hermien Kan. Inmiddels is er een grote MRI 
onderzoeksgroep die zich bezighoudt met onderzoek van brein en spieren bij dystrofi-
nopathie. Van die groep wil ik met name bedanken voor de samenwerking Janneke van 
den Bergen, Nathalie Doorenweerd, dr. Eve Dumas, dr. Jos Hendriksen, dr. Hermien Kan, 
dr. Erik Niks en Beatrijs Wokke.
Het idee voor de studie uit hoofdstuk 6 ontstond toen ik samen met dr. Truus Plandsoen 
tijdens de startfase van ons multidisciplinair spreekuur voor kinderen met chronische spier-
ziekten meeliep met het Duchenne spreekuur van dr. Imelda de Groot destijds in revalidatie-
centrum De Trappenberg. Ik kijk terug op een fijne samenwerking met beiden. 
Daarnaast hebben ook vele anderen geholpen om bij de retrospectieve studies patiënten te 
traceren en oude, papieren, statussen na te slaan; zonder hun inzet waren de studies uit de 
hoofdstukken 2 en 3 niet mogelijk geweest. In het bijzonder wil ik de collega’s werkzaam in 
andere centra noemen: dr. Esther Brusse, prof. dr. Pieter van Doorn, Elly Ippel, dr. Anneke van 
der Kooi, Jan Post, dr. Aad Verrips, prof. dr. Marianne de Visser en dr. Nicol Voermans. 
De ideeën voor de studies van de hoofdstukken 2 en 3 zijn gegroeid bij de gezamenlijke 
besprekingen met de afdeling klinische genetica. Dr. Ieke Ginjaar heeft mij wegwijs ge-
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maakt in de genetische onderwerpen en geholpen met het interpreteren van data die 
zeer lang geleden zijn ingestuurd. Ik denk ook met plezier terug aan de samenwerking 
met dr. Paula Helderman bij ons gezamenlijke artikel uit hoofdstuk 3. 
Mijn belangstelling voor de neuromusculaire ziekten werd gewekt in Leiden, mede door 
het enthousiasme van prof. dr. Jan Verschuuren, die nu mijn promotor is. Het fellowship 
neuromusculaire ziekten was de kers op de taart, waarbij ik de gelegenheid kreeg om in 
drie centra klinische ervaring op te doen. Het was inspirerend en leerzaam de verschillen 
in stijl van werken te zien. 
De status aparte als staflid met promotieopdracht was niet altijd gemakkelijk. “It always 
seems impossible until it’s done” (Nelson Mandela) kan ik beamen. Ik heb het gewaardeerd 
dat mijn collega’s niet steeds vroegen hoe mijn proefschrift vorderde.
Hierbij wil ik gebruik maken van de gelegenheid om twee clinici waarvan ik veel geleerd 
heb postuum te noemen: dr. Peter Kreek, in leven internist in Amersfoort, en mijn eer-
ste supervisor. Zijn stijl van opleiden had iets onconventioneels, en hij nam het altijd op 
voor de (jonge) assistenten. Hij kwam, ook als hij geen dienst had, op zaterdag visite lo-
pen bij zijn eigen patiënten. Van zijn klinische blik heb ik veel geleerd en zijn lijfspreuk 
“Il faut cultiver notre jardin” (Voltaire) in herinnering gehouden.
Prof. dr. Herman Busch, in leven neuroloog in Rotterdam. Hij had een schat aan klinische 
kennis en ervaring en als assistent kon je altijd bij hem terecht met een vraag. Hij liet je 
overigens vooral zelf het antwoord te bedenken. 
Zonder een stabiel thuisfront was de eindfase niet bereikt. Lisette Visser is al ruim 10 jaar 
het rustpunt thuis na schooltijd voor de kinderen en zij zorgt dat wij als gezin in elk geval 
de helft van de week ’s-avonds op tijd warm eten. Ronald, rots in de branding, is er altijd 
wanneer nodig en ook bereid de flexibiliteit op te brengen die nodig is in een gezin met 
twee werkende ouders en schoolgaande kinderen. Tot slot, Laurine en Reinier, jullie zijn 
een bron van heel veel vreugde, en dankzij jullie is het gemakkelijker een hoop zaken 
relatief te zien.
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List of abbreviations 
aD   Autosomal dominant
aDHD  Attention-deficit and hyperactivity disorder 
aON  Antisense oligonucleotide
ar   Autosomal recessive
axD  Axial diffusivity
BMD  Becker muscular dystrophy
CK   Creatine kinase
CPt2  Carnitine palmitoyltransferase II
DM1  Myotonic dystrophy type 1
DM2  Myotonic dystrophy type 2
DMD  Duchenne muscular dystrophy
DtI  Diffusion tensor imaging
ECG  Electrocardiography
EFNS  European federation of neurological societies
EMG  Electromyography
Fa   Fractional anisotropy
FSIQ  Full scale intelligence quotient
Hr- MCa High resolution melting curve analysis
ICV  Intracranial volume
LDGa  Laboratory for Diagnostic Genome Analysis 
LGMD  Limb girdle muscular dystrophy
MD  Mean diffusivity
MH  Malignant hyperthermia
MLPa   Multiplex ligation-dependant probe amplification 
MMD   Miyoshi-type muscular dystrophy
MND   Motor neuron disease 
M-PCr  Multiplex-Polymerase chain reaction 
MrI   Magnetic resonance imaging 
NPE   Neuropsychological examination 
OCD   Obsessive-compulsive disorder 
PrOMM  Proximal myotonic myopathy 
rD   Radial diffusivity 
SD   Standard deviation 
SDS   Standard deviation score
SDQ   Strengths and Difficulties Questionnaire
SEM   Standard error of the mean
SMa   Spinal muscular atrophy 
SMN1   Survival motor neuron 1 
tBV  Total brain volume
U/l   Units/liter 
VBM   Voxel based morphometry 
WB   Western Blot analysis 
WCB   Wheelchair bound
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